Back to results

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Primary Purpose

Pulmonary Disease, Chronic Obstructive

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

tiotropium 18 mcg

tiotropium 1.25 mcg (2 actuations/day)

tiotropium 2.5 mcg (2 actuations/day)

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

All patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
Male or female patients 40 years of age or older.
Patients must be current or ex-smokers with a smoking history of ≥10 pack-years. (Patients who have never smoked cigarettes must be excluded)
All patients must have a diagnosis of COPD (P06-12085), and must meet the following criteria: Relatively stable airway obstruction with a post-bronchodilator FEV1 ≤ 70% of predicted normal and post-bronchodilator FEV1 / FVC ≤70%.
Pulmonary function tests (PFTs) were conducted after the inhalation of 400 μg salbutamol / albuterol (preferred), however testing with either 200 μg salbutamol/albuterol or a combination of salbutamol / albuterol with ipratropium bromide (2 to 4 actuations) was acceptable. Other short-acting beta agonists, such as terbutaline, may have been used for the testing. The medication used for the testing was documented. Further, historical data from measurements within the past 6 months either at the site or at a referral site may have been used (see Section 6.2.1 of the CTP, located in Appendix 16.1.1). Subjects were not to have been randomized to the study without the availability of spirometry data at the actual study site.
Eligibility for PFT sub-study: For subjects participating in the spirometry sub-study, historical data may not have been used for inclusion. These subjects must have qualified in the clinic at Visit 1 after performing a baseline measurement. These subjects performed a pre-dose PFT which was followed by the administration of 400 μg salbutamol / albuterol only (no other short-acting beta agonist was allowed), followed by a post-dose PFT for qualification.
Able to inhale from the HandiHaler® and the Respimat® devices.

Exclusion criteria:

Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patients ability to participate in the study.
Patients with a recent history (i.e., six months or less) of myocardial infarction.
Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
Known active tuberculosis.
Patients with a history of asthma, cystic fibrosis, clinically evident bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease.
History of thoracotomy with pulmonary resection. Subjects with a history of thoracotomy for other reasons were to have been evaluated per exclusion criterion 1.
Subject was planning to undergo lung transplant or lung volume reduction surgery (LVRS).
Malignancy for which the subject had undergone resection, radiation, chemotherapy or biological treatments within the last 5 years. Subjects with treated basal cell carcinoma were allowed.
Known respiratory infection or exacerbation of COPD in the 4 weeks prior to randomization.
Known hypersensitivity to anticholinergic drugs, lactose, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the HandiHaler® or Respimat® inhalation solution delivery system.
Known moderate to severe renal impairment (as judged by the investigator).
Known narrow angle glaucoma.
Known significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Subjects whose symptoms were controlled on treatment may have been included.
Use of systemic corticosteroid medication at unstable doses (i.e., less than 6 weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day.
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for at least 3 months prior to and for the duration of the trial.
Significant alcohol or drug abuse within the past 12 months.
Subjects requiring the use of supplemental oxygen therapy for > 12 hours per day.
Subjects who had completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit or subjects who were currently in a pulmonary rehabilitation program that was not maintained throughout the duration of the study.
Subjects who had taken an investigational drug within 30 days prior to the Screening Visit.
Previous participation (receipt of randomized treatment) in this study.
Subjects who were currently participating in an interventional study.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Experimental

Arm Label

tiotropium 2.5 mcg and placebo

tiotropium 18 mcg and placebo

tiotropium 5 mcg and placebo

Arm Description

Patients receive one of the active tiotropium arms daily

Outcomes

Primary Outcome Measures

Time to All-Cause Mortality

Number of patients with all-cause mortality

Time to First COPD Exacerbation

Defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines). "Onset of exacerbation" was defined by the onset of first recorded symptom. The "end of exacerbation" was decided by the investigator based on clinical judgement. Exacerbations were classified as follows: Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization.

Secondary Outcome Measures

Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients)

Trough forced expiratory volume in one second (FEV1) over 120 weeks (in a substudy of 1370 patients)

Number of COPD Exacerbations

The number of COPD exacerbations. COPD exacerbation defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines).

Time to First Hospitalization Associated With COPD Exacerbation

The results presented below are for the patients with hospitalizations due to COPD exacerbations.

Number of Hospitalizations Associated With COPD Exacerbation

Total number of hospitalizations associated with COPD exacerbation.

Time to First Moderate to Severe COPD Exacerbation

COPD exacerbation defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines). Exacerbations classified as follows: Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization. Results presented below are number of patients with moderate to severe exacerbations.

Time to Onset of First Major Adverse Cardiovascular Event (MACE)

Time to onset of first major adverse cardiovascular event (MACE). MACE was defined as: Fatal event in the system organ classes of cardiac and vascular disorders, Preferred terms: sudden death, cardiac death, sudden cardiac death, Outcome events of myocardial infarction (serious and non-serious), Outcome events of stroke (serious and non-serious) and Outcome events of TIA (serious and non-serious). The results presented below are for the number of patients with MACE.

Time to Death From Major Adverse Cardiovascular Event (MACE)

The results presented below are number of patients with death from MACE.

Full Information

NCT ID

NCT01126437

First Posted

May 6, 2010

Last Updated

May 20, 2014

Sponsor

Boehringer Ingelheim

1. Study Identification

Unique Protocol Identification Number

NCT01126437

Brief Title

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Official Title

A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

Study Type

Interventional

2. Study Status

Record Verification Date

May 2014

Overall Recruitment Status

Completed

Study Start Date

May 2010 (undefined)

Primary Completion Date

May 2013 (Actual)

Study Completion Date

May 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary

Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pulmonary Disease, Chronic Obstructive

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

Double

Allocation

Randomized

Enrollment

17183 (Actual)

8. Arms, Groups, and Interventions

Arm Title

tiotropium 2.5 mcg and placebo

Arm Type

Experimental

Arm Description

Patients receive one of the active tiotropium arms daily

Arm Title

tiotropium 18 mcg and placebo

Arm Type

Active Comparator

Arm Description

Patients receive one of the active tiotropium arms daily

Arm Title

tiotropium 5 mcg and placebo

Arm Type

Experimental

Arm Description

Patients receive one of the active tiotropium arms daily

Intervention Type

Drug

Intervention Name(s)

tiotropium 18 mcg

Intervention Description

HandiHaler

Intervention Type

Drug

Intervention Name(s)

tiotropium 1.25 mcg (2 actuations/day)

Intervention Description

soft mist inhaler 2 actuations=2 puffs/day

Intervention Type

Drug

Intervention Name(s)

tiotropium 2.5 mcg (2 actuations/day)

Intervention Description

soft mist inhaler (2 actuations=2 puffs/day)

Primary Outcome Measure Information:

Title

Time to All-Cause Mortality

Description

Number of patients with all-cause mortality

Time Frame

Up to 3 years

Title

Time to First COPD Exacerbation

Description

Time Frame

Up to 3 years

Secondary Outcome Measure Information:

Title

Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients)

Description

Trough forced expiratory volume in one second (FEV1) over 120 weeks (in a substudy of 1370 patients)

Time Frame

Up to 3 years

Title

Number of COPD Exacerbations

Description

Time Frame

Up to 3 years

Title

Time to First Hospitalization Associated With COPD Exacerbation

Description

The results presented below are for the patients with hospitalizations due to COPD exacerbations.

Time Frame

Up to 3 years

Title

Number of Hospitalizations Associated With COPD Exacerbation

Description

Total number of hospitalizations associated with COPD exacerbation.

Time Frame

Up to 3 years

Title

Time to First Moderate to Severe COPD Exacerbation

Description

Time Frame

Up to 3 years

Title

Time to Onset of First Major Adverse Cardiovascular Event (MACE)

Description

Time Frame

Up to 3 years

Title

Time to Death From Major Adverse Cardiovascular Event (MACE)

Description

The results presented below are number of patients with death from MACE.

Time Frame

Up to 3 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

40 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion criteria: All patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions. Male or female patients 40 years of age or older. Patients must be current or ex-smokers with a smoking history of ≥10 pack-years. (Patients who have never smoked cigarettes must be excluded) All patients must have a diagnosis of COPD (P06-12085), and must meet the following criteria: Relatively stable airway obstruction with a post-bronchodilator FEV1 ≤ 70% of predicted normal and post-bronchodilator FEV1 / FVC ≤70%. Pulmonary function tests (PFTs) were conducted after the inhalation of 400 μg salbutamol / albuterol (preferred), however testing with either 200 μg salbutamol/albuterol or a combination of salbutamol / albuterol with ipratropium bromide (2 to 4 actuations) was acceptable. Other short-acting beta agonists, such as terbutaline, may have been used for the testing. The medication used for the testing was documented. Further, historical data from measurements within the past 6 months either at the site or at a referral site may have been used (see Section 6.2.1 of the CTP, located in Appendix 16.1.1). Subjects were not to have been randomized to the study without the availability of spirometry data at the actual study site. Eligibility for PFT sub-study: For subjects participating in the spirometry sub-study, historical data may not have been used for inclusion. These subjects must have qualified in the clinic at Visit 1 after performing a baseline measurement. These subjects performed a pre-dose PFT which was followed by the administration of 400 μg salbutamol / albuterol only (no other short-acting beta agonist was allowed), followed by a post-dose PFT for qualification. Able to inhale from the HandiHaler® and the Respimat® devices. Exclusion criteria: Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patients ability to participate in the study. Patients with a recent history (i.e., six months or less) of myocardial infarction. Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year. Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year. Known active tuberculosis. Patients with a history of asthma, cystic fibrosis, clinically evident bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease. History of thoracotomy with pulmonary resection. Subjects with a history of thoracotomy for other reasons were to have been evaluated per exclusion criterion 1. Subject was planning to undergo lung transplant or lung volume reduction surgery (LVRS). Malignancy for which the subject had undergone resection, radiation, chemotherapy or biological treatments within the last 5 years. Subjects with treated basal cell carcinoma were allowed. Known respiratory infection or exacerbation of COPD in the 4 weeks prior to randomization. Known hypersensitivity to anticholinergic drugs, lactose, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the HandiHaler® or Respimat® inhalation solution delivery system. Known moderate to severe renal impairment (as judged by the investigator). Known narrow angle glaucoma. Known significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Subjects whose symptoms were controlled on treatment may have been included. Use of systemic corticosteroid medication at unstable doses (i.e., less than 6 weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for at least 3 months prior to and for the duration of the trial. Significant alcohol or drug abuse within the past 12 months. Subjects requiring the use of supplemental oxygen therapy for > 12 hours per day. Subjects who had completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit or subjects who were currently in a pulmonary rehabilitation program that was not maintained throughout the duration of the study. Subjects who had taken an investigational drug within 30 days prior to the Screening Visit. Previous participation (receipt of randomized treatment) in this study. Subjects who were currently participating in an interventional study.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Boehringer Ingelheim

Organizational Affiliation

Boehringer Ingelheim

Official's Role

Study Chair

Facility Information:

Facility Name

205.452.01107 Boehringer Ingelheim Investigational Site

City

Athens

State/Province

Alabama

Country

United States

Facility Name

205.452.01023 Boehringer Ingelheim Investigational Site

City

Birmingham

State/Province

Alabama

Country

United States

Facility Name

205.452.01035 Boehringer Ingelheim Investigational Site

City

Birmingham

State/Province

Alabama

Country

United States

Facility Name

205.452.01052 Boehringer Ingelheim Investigational Site

City

Birmingham

State/Province

Alabama

Country

United States

Facility Name

205.452.01219 Boehringer Ingelheim Investigational Site

City

Birmingham

State/Province

Alabama

Country

United States

Facility Name

205.452.01227 Boehringer Ingelheim Investigational Site

City

Birmingham

State/Province

Alabama

Country

United States

Facility Name

205.452.01280 Boehringer Ingelheim Investigational Site

City

Birmingham

State/Province

Alabama

Country

United States

Facility Name

205.452.01198 Boehringer Ingelheim Investigational Site

City

Florence

State/Province

Alabama

Country

United States

Facility Name

205.452.01244 Boehringer Ingelheim Investigational Site

City

Mobile

State/Province

Alabama

Country

United States

Facility Name

205.452.01041 Boehringer Ingelheim Investigational Site

City

Montgomery

State/Province

Alabama

Country

United States

Facility Name

205.452.01070 Boehringer Ingelheim Investigational Site

City

Anchorage

State/Province

Alaska

Country

United States

Facility Name

205.452.01218 Boehringer Ingelheim Investigational Site

City

Chandler

State/Province

Arizona

Country

United States

Facility Name

205.452.01175 Boehringer Ingelheim Investigational Site

City

Mesa

State/Province

Arizona

Country

United States

Facility Name

205.452.01200 Boehringer Ingelheim Investigational Site

City

Mesa

State/Province

Arizona

Country

United States

Facility Name

205.452.01317 Boehringer Ingelheim Investigational Site

City

Mesa

State/Province

Arizona

Country

United States

Facility Name

205.452.01350 Boehringer Ingelheim Investigational Site

City

Pheonix

State/Province

Arizona

Country

United States

Facility Name

205.452.01254 Boehringer Ingelheim Investigational Site

City

Phoenix

State/Province

Arizona

Country

United States

Facility Name

205.452.01283 Boehringer Ingelheim Investigational Site

City

Phoenix

State/Province

Arizona

Country

United States

Facility Name

205.452.01315 Boehringer Ingelheim Investigational Site

City

Tempe

State/Province

Arizona

Country

United States

Facility Name

205.452.01158 Boehringer Ingelheim Investigational Site

City

Tucson

State/Province

Arizona

Country

United States

Facility Name

205.452.01161 Boehringer Ingelheim Investigational Site

City

Tucson

State/Province

Arizona

Country

United States

Facility Name

205.452.01302 Boehringer Ingelheim Investigational Site

City

Anaheim

State/Province

California

Country

United States

Facility Name

205.452.01038 Boehringer Ingelheim Investigational Site

City

Encinitas

State/Province

California

Country

United States

Facility Name

205.452.01313 Boehringer Ingelheim Investigational Site

City

Fountain Valley

State/Province

California

Country

United States

Facility Name

205.452.01375 Boehringer Ingelheim Investigational Site

City

Fountain Valley

State/Province

California

Country

United States

Facility Name

205.452.01074 Boehringer Ingelheim Investigational Site

City

Fullerton

State/Province

California

Country

United States

Facility Name

205.452.01345 Boehringer Ingelheim Investigational Site

City

Lancaster

State/Province

California

Country

United States

Facility Name

205.452.01171 Boehringer Ingelheim Investigational Site

City

Lincoln

State/Province

California

Country

United States

Facility Name

205.452.01339 Boehringer Ingelheim Investigational Site

City

Lomita

State/Province

California

Country

United States

Facility Name

205.452.01298 Boehringer Ingelheim Investigational Site

City

Los Angeles

State/Province

California

Country

United States

Facility Name

205.452.01356 Boehringer Ingelheim Investigational Site

City

Los Angeles

State/Province

California

Country

United States

Facility Name

205.452.01148 Boehringer Ingelheim Investigational Site

City

Orange

State/Province

California

Country

United States

Facility Name

205.452.01111 Boehringer Ingelheim Investigational Site

City

Palm Springs

State/Province

California

Country

United States

Facility Name

205.452.01147 Boehringer Ingelheim Investigational Site

City

Paramount

State/Province

California

Country

United States

Facility Name

205.452.01071 Boehringer Ingelheim Investigational Site

City

Poway

State/Province

California

Country

United States

Facility Name

205.452.01089 Boehringer Ingelheim Investigational Site

City

Rancho Cucamonga

State/Province

California

Country

United States

Facility Name

205.452.01097 Boehringer Ingelheim Investigational Site

City

Redlands

State/Province

California

Country

United States

Facility Name

205.452.01078 Boehringer Ingelheim Investigational Site

City

San Diego

State/Province

California

Country

United States

Facility Name

205.452.01176 Boehringer Ingelheim Investigational Site

City

San Diego

State/Province

California

Country

United States

Facility Name

205.452.01346 Boehringer Ingelheim Investigational Site

City

San Diego

State/Province

California

Country

United States

Facility Name

205.452.01306 Boehringer Ingelheim Investigational Site

City

San Jose

State/Province

California

Country

United States

Facility Name

205.452.01297 Boehringer Ingelheim Investigational Site

City

Santa Barbara

State/Province

California

Country

United States

Facility Name

205.452.01362 Boehringer Ingelheim Investigational Site

City

Tustin

State/Province

California

Country

United States

Facility Name

205.452.01225 Boehringer Ingelheim Investigational Site

City

Victorville

State/Province

California

Country

United States

Facility Name

205.452.01224 Boehringer Ingelheim Investigational Site

City

Walnut Creek

State/Province

California

Country

United States

Facility Name

205.452.01236 Boehringer Ingelheim Investigational Site

City

Wildomar

State/Province

California

Country

United States

Facility Name

205.452.01049 Boehringer Ingelheim Investigational Site

City

Colorado Springs

State/Province

Colorado

Country

United States

Facility Name

205.452.01245 Boehringer Ingelheim Investigational Site

City

Colorado Springs

State/Province

Colorado

Country

United States

Facility Name

205.452.01351 Boehringer Ingelheim Investigational Site

City

Denver

State/Province

Colorado

Country

United States

Facility Name

205.452.01018 Boehringer Ingelheim Investigational Site

City

Fort Collins

State/Province

Colorado

Country

United States

Facility Name

205.452.01005 Boehringer Ingelheim Investigational Site

City

Wheat Ridge

State/Province

Colorado

Country

United States

Facility Name

205.452.01024 Boehringer Ingelheim Investigational Site

City

Wheat Ridge

State/Province

Colorado

Country

United States

Facility Name

205.452.01199 Boehringer Ingelheim Investigational Site

City

Danbury

State/Province

Connecticut

Country

United States

Facility Name

205.452.01054 Boehringer Ingelheim Investigational Site

City

Hartford

State/Province

Connecticut

Country

United States

Facility Name

205.452.01072 Boehringer Ingelheim Investigational Site

City

Norwalk

State/Province

Connecticut

Country

United States

Facility Name

205.452.01040 Boehringer Ingelheim Investigational Site

City

Stamford

State/Province

Connecticut

Country

United States

Facility Name

205.452.01109 Boehringer Ingelheim Investigational Site

City

Waterbury

State/Province

Connecticut

Country

United States

Facility Name

205.452.01308 Boehringer Ingelheim Investigational Site

City

Newark

State/Province

Delaware

Country

United States

Facility Name

205.452.01011 Boehringer Ingelheim Investigational Site

City

Clearwater

State/Province

Florida

Country

United States

Facility Name

205.452.01209 Boehringer Ingelheim Investigational Site

City

Hialeah

State/Province

Florida

Country

United States

Facility Name

205.452.01360 Boehringer Ingelheim Investigational Site

City

Homestead

State/Province

Florida

Country

United States

Facility Name

205.452.01241 Boehringer Ingelheim Investigational Site

City

Jacksonville

State/Province

Florida

Country

United States

Facility Name

205.452.01337 Boehringer Ingelheim Investigational Site

City

Jacksonville

State/Province

Florida

Country

United States

Facility Name

205.452.01343 Boehringer Ingelheim Investigational Site

City

Jacksonville

State/Province

Florida

Country

United States

Facility Name

205.452.01184 Boehringer Ingelheim Investigational Site

City

Jupiter

State/Province

Florida

Country

United States

Facility Name

205.452.01138 Boehringer Ingelheim Investigational Site

City

Miami

State/Province

Florida

Country

United States

Facility Name

205.452.01246 Boehringer Ingelheim Investigational Site

City

Miami

State/Province

Florida

Country

United States

Facility Name

205.452.01321 Boehringer Ingelheim Investigational Site

City

Miami

State/Province

Florida

Country

United States

Facility Name

205.452.01290 Boehringer Ingelheim Investigational Site

City

New Port Richey

State/Province

Florida

Country

United States

Facility Name

205.452.01203 Boehringer Ingelheim Investigational Site

City

Ocala

State/Province

Florida

Country

United States

Facility Name

205.452.01174 Boehringer Ingelheim Investigational Site

City

Orlando

State/Province

Florida

Country

United States

Facility Name

205.452.01135 Boehringer Ingelheim Investigational Site

City

Ormond Beach

State/Province

Florida

Country

United States

Facility Name

205.452.01173 Boehringer Ingelheim Investigational Site

City

Oviedo

State/Province

Florida

Country

United States

Facility Name

205.452.01195 Boehringer Ingelheim Investigational Site

City

Panama City

State/Province

Florida

Country

United States

Facility Name

205.452.01197 Boehringer Ingelheim Investigational Site

City

Panama City

State/Province

Florida

Country

United States

Facility Name

205.452.01239 Boehringer Ingelheim Investigational Site

City

Pembroke Pines

State/Province

Florida

Country

United States

Facility Name

205.452.01247 Boehringer Ingelheim Investigational Site

City

Pembroke Pines

State/Province

Florida

Country

United States

Facility Name

205.452.01286 Boehringer Ingelheim Investigational Site

City

Pembroke Pines

State/Province

Florida

Country

United States

Facility Name

205.452.01240 Boehringer Ingelheim Investigational Site

City

Pensacola

State/Province

Florida

Country

United States

Facility Name

205.452.01260 Boehringer Ingelheim Investigational Site

City

Ponte Vedra

State/Province

Florida

Country

United States

Facility Name

205.452.01092 Boehringer Ingelheim Investigational Site

City

Rockledge

State/Province

Florida

Country

United States

Facility Name

205.452.01251 Boehringer Ingelheim Investigational Site

City

Sarasota

State/Province

Florida

Country

United States

Facility Name

205.452.01133 Boehringer Ingelheim Investigational Site

City

St. Petersburg

State/Province

Florida

Country

United States

Facility Name

205.452.01136 Boehringer Ingelheim Investigational Site

City

St. Petersburg

State/Province

Florida

Country

United States

Facility Name

205.452.01207 Boehringer Ingelheim Investigational Site

City

St. Petersburg

State/Province

Florida

Country

United States

Facility Name

205.452.01134 Boehringer Ingelheim Investigational Site

City

Tamarac

State/Province

Florida

Country

United States

Facility Name

205.452.01231 Boehringer Ingelheim Investigational Site

City

Tamarac

State/Province

Florida

Country

United States

Facility Name

205.452.01025 Boehringer Ingelheim Investigational Site

City

Tampa

State/Province

Florida

Country

United States

Facility Name

205.452.01250 Boehringer Ingelheim Investigational Site

City

Tampa

State/Province

Florida

Country

United States

Facility Name

205.452.01060 Boehringer Ingelheim Investigational Site

City

Winter Park

State/Province

Florida

Country

United States

Facility Name

205.452.01130 Boehringer Ingelheim Investigational Site

City

Atlanta

State/Province

Georgia

Country

United States

Facility Name

205.452.01047 Boehringer Ingelheim Investigational Site

City

Austell

State/Province

Georgia

Country

United States

Facility Name

205.452.01255 Boehringer Ingelheim Investigational Site

City

Columbus

State/Province

Georgia

Country

United States

Facility Name

205.452.01012 Boehringer Ingelheim Investigational Site

City

Conyers

State/Province

Georgia

Country

United States

Facility Name

205.452.01299 Boehringer Ingelheim Investigational Site

City

Gainesville

State/Province

Georgia

Country

United States

Facility Name

205.452.01288 Boehringer Ingelheim Investigational Site

City

Lawrenceville

State/Province

Georgia

Country

United States

Facility Name

205.452.01090 Boehringer Ingelheim Investigational Site

City

Snellville

State/Province

Georgia

Country

United States

Facility Name

205.452.01100 Boehringer Ingelheim Investigational Site

City

Honolulu

State/Province

Hawaii

Country

United States

Facility Name

205.452.01165 Boehringer Ingelheim Investigational Site

City

Boise

State/Province

Idaho

Country

United States

Facility Name

205.452.01059 Boehringer Ingelheim Investigational Site

City

Coeur d'Alene

State/Province

Idaho

Country

United States

Facility Name

205.452.01062 Boehringer Ingelheim Investigational Site

City

Eagle

State/Province

Idaho

Country

United States

Facility Name

205.452.01166 Boehringer Ingelheim Investigational Site

City

Hayden Lake

State/Province

Idaho

Country

United States

Facility Name

205.452.01275 Boehringer Ingelheim Investigational Site

City

Meridian

State/Province

Idaho

Country

United States

Facility Name

205.452.01330 Boehringer Ingelheim Investigational Site

City

Arlington Heights

State/Province

Illinois

Country

United States

Facility Name

205.452.01248 Boehringer Ingelheim Investigational Site

City

Belleville

State/Province

Illinois

Country

United States

Facility Name

205.452.01278 Boehringer Ingelheim Investigational Site

City

Chicago

State/Province

Illinois

Country

United States

Facility Name

205.452.01371 Boehringer Ingelheim Investigational Site

City

Downer Grove

State/Province

Illinois

Country

United States

Facility Name

205.452.01235 Boehringer Ingelheim Investigational Site

City

Lombard

State/Province

Illinois

Country

United States

Facility Name

205.452.01180 Boehringer Ingelheim Investigational Site

City

O'Fallon

State/Province

Illinois

Country

United States

Facility Name

205.452.01268 Boehringer Ingelheim Investigational Site

City

Oak Park

State/Province

Illinois

Country

United States

Facility Name

205.452.01359 Boehringer Ingelheim Investigational Site

City

Quincy

State/Province

Illinois

Country

United States

Facility Name

205.452.01347 Boehringer Ingelheim Investigational Site

City

Brownsburg

State/Province

Indiana

Country

United States

Facility Name

205.452.01153 Boehringer Ingelheim Investigational Site

City

Evansville

State/Province

Indiana

Country

United States

Facility Name

205.452.01301 Boehringer Ingelheim Investigational Site

City

Fishers

State/Province

Indiana

Country

United States

Facility Name

205.452.01141 Boehringer Ingelheim Investigational Site

City

Franklin

State/Province

Indiana

Country

United States

Facility Name

205.452.01137 Boehringer Ingelheim Investigational Site

City

Lafayette

State/Province

Indiana

Country

United States

Facility Name

205.452.01263 Boehringer Ingelheim Investigational Site

City

Muncie

State/Province

Indiana

Country

United States

Facility Name

205.452.01284 Boehringer Ingelheim Investigational Site

City

Council Bluffs

State/Province

Iowa

Country

United States

Facility Name

205.452.01021 Boehringer Ingelheim Investigational Site

City

Dubuque

State/Province

Iowa

Country

United States

Facility Name

205.452.01305 Boehringer Ingelheim Investigational Site

City

Lansing

State/Province

Kansas

Country

United States

Facility Name

205.452.01304 Boehringer Ingelheim Investigational Site

City

Olathe

State/Province

Kansas

Country

United States

Facility Name

205.452.01125 Boehringer Ingelheim Investigational Site

City

Overland Park

State/Province

Kansas

Country

United States

Facility Name

205.452.01068 Boehringer Ingelheim Investigational Site

City

Topeka

State/Province

Kansas

Country

United States

Facility Name

205.452.01063 Boehringer Ingelheim Investigational Site

City

Bowling Green

State/Province

Kentucky

Country

United States

Facility Name

205.452.01206 Boehringer Ingelheim Investigational Site

City

Fort Mitchell

State/Province

Kentucky

Country

United States

Facility Name

205.452.01289 Boehringer Ingelheim Investigational Site

City

Louisville

State/Province

Kentucky

Country

United States

Facility Name

205.452.01152 Boehringer Ingelheim Investigational Site

City

Paducah

State/Province

Kentucky

Country

United States

Facility Name

205.452.01015 Boehringer Ingelheim Investigational Site

City

Lafayette

State/Province

Louisiana

Country

United States

Facility Name

205.452.01091 Boehringer Ingelheim Investigational Site

City

Shreveport

State/Province

Louisiana

Country

United States

Facility Name

205.452.01329 Boehringer Ingelheim Investigational Site

City

Shreveport

State/Province

Louisiana

Country

United States

Facility Name

205.452.01364 Boehringer Ingelheim Investigational Site

City

Auburn

State/Province

Maine

Country

United States

Facility Name

205.452.01169 Boehringer Ingelheim Investigational Site

City

Bangor

State/Province

Maine

Country

United States

Facility Name

205.452.01022 Boehringer Ingelheim Investigational Site

City

Biddeford

State/Province

Maine

Country

United States

Facility Name

205.452.01053 Boehringer Ingelheim Investigational Site

City

Baltimore

State/Province

Maryland

Country

United States

Facility Name

205.452.01190 Boehringer Ingelheim Investigational Site

City

Elkridge

State/Province

Maryland

Country

United States

Facility Name

205.452.01336 Boehringer Ingelheim Investigational Site

City

Hollywood

State/Province

Maryland

Country

United States

Facility Name

205.452.01238 Boehringer Ingelheim Investigational Site

City

Towson

State/Province

Maryland

Country

United States

Facility Name

205.452.01243 Boehringer Ingelheim Investigational Site

City

Towson

State/Province

Maryland

Country

United States

Facility Name

205.452.01366 Boehringer Ingelheim Investigational Site

City

Fall River

State/Province

Massachusetts

Country

United States

Facility Name

205.452.01269 Boehringer Ingelheim Investigational Site

City

Haverhill

State/Province

Massachusetts

Country

United States

Facility Name

205.452.01208 Boehringer Ingelheim Investigational Site

City

New Bedford

State/Province

Massachusetts

Country

United States

Facility Name

205.452.01170 Boehringer Ingelheim Investigational Site

City

Worcester

State/Province

Massachusetts

Country

United States

Facility Name

205.452.01270 Boehringer Ingelheim Investigational Site

City

Ann Arbor

State/Province

Michigan

Country

United States

Facility Name

205.452.01349 Boehringer Ingelheim Investigational Site

City

Benzonia

State/Province

Michigan

Country

United States

Facility Name

205.452.01365 Boehringer Ingelheim Investigational Site

City

Chelsea

State/Province

Michigan

Country

United States

Facility Name

205.452.01149 Boehringer Ingelheim Investigational Site

City

Chesterfield

State/Province

Michigan

Country

United States

Facility Name

205.452.01146 Boehringer Ingelheim Investigational Site

City

Detroit

State/Province

Michigan

Country

United States

Facility Name

205.452.01139 Boehringer Ingelheim Investigational Site

City

Interlochen

State/Province

Michigan

Country

United States

Facility Name

205.452.01080 Boehringer Ingelheim Investigational Site

City

Kalamazoo

State/Province

Michigan

Country

United States

Facility Name

205.452.01310 Boehringer Ingelheim Investigational Site

City

Stevensville

State/Province

Michigan

Country

United States

Facility Name

205.452.01122 Boehringer Ingelheim Investigational Site

City

Traverse City

State/Province

Michigan

Country

United States

Facility Name

205.452.01081 Boehringer Ingelheim Investigational Site

City

Troy

State/Province

Michigan

Country

United States

Facility Name

205.452.01221 Boehringer Ingelheim Investigational Site

City

Troy

State/Province

Michigan

Country

United States

Facility Name

205.452.01205 Boehringer Ingelheim Investigational Site

City

Chaska

State/Province

Minnesota

Country

United States

Facility Name

205.452.01211 Boehringer Ingelheim Investigational Site

City

Edina

State/Province

Minnesota

Country

United States

Facility Name

205.452.01104 Boehringer Ingelheim Investigational Site

City

Fridley

State/Province

Minnesota

Country

United States

Facility Name

205.452.01113 Boehringer Ingelheim Investigational Site

City

Minneapolis

State/Province

Minnesota

Country

United States

Facility Name

205.452.01042 Boehringer Ingelheim Investigational Site

City

Rochester

State/Province

Minnesota

Country

United States

Facility Name

205.452.01019 Boehringer Ingelheim Investigational Site

City

Olive Branch

State/Province

Mississippi

Country

United States

Facility Name

205.452.01014 Boehringer Ingelheim Investigational Site

City

Chesterfield

State/Province

Missouri

Country

United States

Facility Name

205.452.01129 Boehringer Ingelheim Investigational Site

City

St. Charles

State/Province

Missouri

Country

United States

Facility Name

205.452.01110 Boehringer Ingelheim Investigational Site

City

St. Louis

State/Province

Missouri

Country

United States

Facility Name

205.452.01179 Boehringer Ingelheim Investigational Site

City

West Plains

State/Province

Missouri

Country

United States

Facility Name

205.452.01226 Boehringer Ingelheim Investigational Site

City

Billings

State/Province

Montana

Country

United States

Facility Name

205.452.01076 Boehringer Ingelheim Investigational Site

City

Butte

State/Province

Montana

Country

United States

Facility Name

205.452.01196 Boehringer Ingelheim Investigational Site

City

Missoula

State/Province

Montana

Country

United States

Facility Name

205.452.01150 Boehringer Ingelheim Investigational Site

City

Bellevue

State/Province

Nebraska

Country

United States

Facility Name

205.452.01187 Boehringer Ingelheim Investigational Site

City

Fremont

State/Province

Nebraska

Country

United States

Facility Name

205.452.01155 Boehringer Ingelheim Investigational Site

City

Omaha

State/Province

Nebraska

Country

United States

Facility Name

205.452.01073 Boehringer Ingelheim Investigational Site

City

Henderson

State/Province

Nevada

Country

United States

Facility Name

205.452.01031 Boehringer Ingelheim Investigational Site

City

Las Vegas

State/Province

Nevada

Country

United States

Facility Name

205.452.01261 Boehringer Ingelheim Investigational Site

City

Las Vegas

State/Province

Nevada

Country

United States

Facility Name

205.452.01026 Boehringer Ingelheim Investigational Site

City

Lebanon

State/Province

New Hampshire

Country

United States

Facility Name

205.452.01369 Boehringer Ingelheim Investigational Site

City

Newington

State/Province

New Hampshire

Country

United States

Facility Name

205.452.01296 Boehringer Ingelheim Investigational Site

City

Ocean

State/Province

New Jersey

Country

United States

Facility Name

205.452.01046 Boehringer Ingelheim Investigational Site

City

Toms River

State/Province

New Jersey

Country

United States

Facility Name

205.452.01061 Boehringer Ingelheim Investigational Site

City

Albuquerque

State/Province

New Mexico

Country

United States

Facility Name

205.452.01167 Boehringer Ingelheim Investigational Site

City

Albuquerque

State/Province

New Mexico

Country

United States

Facility Name

205.452.01159 Boehringer Ingelheim Investigational Site

City

Bayside

State/Province

New York

Country

United States

Facility Name

205.452.01163 Boehringer Ingelheim Investigational Site

City

Bronxville

State/Province

New York

Country

United States

Facility Name

205.452.01194 Boehringer Ingelheim Investigational Site

City

Cooperstown

State/Province

New York

Country

United States

Facility Name

205.452.01131 Boehringer Ingelheim Investigational Site

City

Elmira

State/Province

New York

Country

United States

Facility Name

205.452.01142 Boehringer Ingelheim Investigational Site

City

Endwell

State/Province

New York

Country

United States

Facility Name

205.452.01192 Boehringer Ingelheim Investigational Site

City

Glens Falls

State/Province

New York

Country

United States

Facility Name

205.452.01279 Boehringer Ingelheim Investigational Site

City

Great Neck

State/Province

New York

Country

United States

Facility Name

205.452.01328 Boehringer Ingelheim Investigational Site

City

Honeoye Falls

State/Province

New York

Country

United States

Facility Name

205.452.01118 Boehringer Ingelheim Investigational Site

City

New Windsor

State/Province

New York

Country

United States

Facility Name

205.452.01127 Boehringer Ingelheim Investigational Site

City

New York

State/Province

New York

Country

United States

Facility Name

205.452.01058 Boehringer Ingelheim Investigational Site

City

Rochester

State/Province

New York

Country

United States

Facility Name

205.452.01085 Boehringer Ingelheim Investigational Site

City

Syracuse

State/Province

New York

Country

United States

Facility Name

205.452.01293 Boehringer Ingelheim Investigational Site

City

Syracuse

State/Province

New York

Country

United States

Facility Name

205.452.01151 Boehringer Ingelheim Investigational Site

City

Vestal

State/Province

New York

Country

United States

Facility Name

205.452.01188 Boehringer Ingelheim Investigational Site

City

Westfield

State/Province

New York

Country

United States

Facility Name

205.452.01271 Boehringer Ingelheim Investigational Site

City

Asheville

State/Province

North Carolina

Country

United States

Facility Name

205.452.01101 Boehringer Ingelheim Investigational Site

City

Burlington

State/Province

North Carolina

Country

United States

Facility Name

205.452.01264 Boehringer Ingelheim Investigational Site

City

Calabash

State/Province

North Carolina

Country

United States

Facility Name

205.452.01168 Boehringer Ingelheim Investigational Site

City

Charlotte

State/Province

North Carolina

Country

United States

Facility Name

205.452.01108 Boehringer Ingelheim Investigational Site

City

Elizabeth City

State/Province

North Carolina

Country

United States

Facility Name

205.452.01033 Boehringer Ingelheim Investigational Site

City

Greensboro

State/Province

North Carolina

Country

United States

Facility Name

205.452.01172 Boehringer Ingelheim Investigational Site

City

Greensboro

State/Province

North Carolina

Country

United States

Facility Name

205.452.01098 Boehringer Ingelheim Investigational Site

City

Hickory

State/Province

North Carolina

Country

United States

Facility Name

205.452.01115 Boehringer Ingelheim Investigational Site

City

Hickory

State/Province

North Carolina

Country

United States

Facility Name

205.452.01128 Boehringer Ingelheim Investigational Site

City

Raleigh

State/Province

North Carolina

Country

United States

Facility Name

205.452.01352 Boehringer Ingelheim Investigational Site

City

Rocky Mount

State/Province

North Carolina

Country

United States

Facility Name

205.452.01348 Boehringer Ingelheim Investigational Site

City

Salisbury

State/Province

North Carolina

Country

United States

Facility Name

205.452.01032 Boehringer Ingelheim Investigational Site

City

Statesville

State/Province

North Carolina

Country

United States

Facility Name

205.452.01276 Boehringer Ingelheim Investigational Site

City

Tabor City

State/Province

North Carolina

Country

United States

Facility Name

205.452.01157 Boehringer Ingelheim Investigational Site

City

Wilmington

State/Province

North Carolina

Country

United States

Facility Name

205.452.01363 Boehringer Ingelheim Investigational Site

City

Winston Salem

State/Province

North Carolina

Country

United States

Facility Name

205.452.01193 Boehringer Ingelheim Investigational Site

City

Canal Fulton

State/Province

Ohio

Country

United States

Facility Name

205.452.01374 Boehringer Ingelheim Investigational Site

City

Centerville

State/Province

Ohio

Country

United States

Facility Name

205.452.01006 Boehringer Ingelheim Investigational Site

City

Cincinnati

State/Province

Ohio

Country

United States

Facility Name

205.452.01373 Boehringer Ingelheim Investigational Site

City

Cincinnati

State/Province

Ohio

Country

United States

Facility Name

205.452.01314 Boehringer Ingelheim Investigational Site

City

Cleveland

State/Province

Ohio

Country

United States

Facility Name

205.452.01210 Boehringer Ingelheim Investigational Site

City

Columbus

State/Province

Ohio

Country

United States

Facility Name

205.452.01232 Boehringer Ingelheim Investigational Site

City

Columbus

State/Province

Ohio

Country

United States

Facility Name

205.452.01309 Boehringer Ingelheim Investigational Site

City

Dayton

State/Province

Ohio

Country

United States

Facility Name

205.452.01140 Boehringer Ingelheim Investigational Site

City

Delaware

State/Province

Ohio

Country

United States

Facility Name

205.452.01084 Boehringer Ingelheim Investigational Site

City

Sylvania

State/Province

Ohio

Country

United States

Facility Name

205.452.01287 Boehringer Ingelheim Investigational Site

City

Toledo

State/Province

Ohio

Country

United States

Facility Name

205.452.01010 Boehringer Ingelheim Investigational Site

City

Oklahoma City

State/Province

Oklahoma

Country

United States

Facility Name

205.452.01094 Boehringer Ingelheim Investigational Site

City

Oklahoma City

State/Province

Oklahoma

Country

United States

Facility Name

205.452.01029 Boehringer Ingelheim Investigational Site

City

Tulsa

State/Province

Oklahoma

Country

United States

Facility Name

205.452.01043 Boehringer Ingelheim Investigational Site

City

Tulsa

State/Province

Oklahoma

Country

United States

Facility Name

205.452.01266 Boehringer Ingelheim Investigational Site

City

Ashland

State/Province

Oregon

Country

United States

Facility Name

205.452.01083 Boehringer Ingelheim Investigational Site

City

Bend

State/Province

Oregon

Country

United States

Facility Name

205.452.01189 Boehringer Ingelheim Investigational Site

City

Corvallis

State/Province

Oregon

Country

United States

Facility Name

205.452.01341 Boehringer Ingelheim Investigational Site

City

Springfield

State/Province

Oregon

Country

United States

Facility Name

205.452.01002 Boehringer Ingelheim Investigational Site

City

Altoona

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01354 Boehringer Ingelheim Investigational Site

City

Beaver

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01143 Boehringer Ingelheim Investigational Site

City

Carnegie

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01320 Boehringer Ingelheim Investigational Site

City

Downingtown

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01323 Boehringer Ingelheim Investigational Site

City

Erie

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01257 Boehringer Ingelheim Investigational Site

City

Jefferson Hills

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01332 Boehringer Ingelheim Investigational Site

City

Langhorne

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01075 Boehringer Ingelheim Investigational Site

City

Norristown

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01087 Boehringer Ingelheim Investigational Site

City

Philadelphia

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01144 Boehringer Ingelheim Investigational Site

City

Philadelphia

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01003 Boehringer Ingelheim Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01361 Boehringer Ingelheim Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01036 Boehringer Ingelheim Investigational Site

City

Pleasant Hills

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01106 Boehringer Ingelheim Investigational Site

City

Uniontown

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01156 Boehringer Ingelheim Investigational Site

City

Uniontown

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01204 Boehringer Ingelheim Investigational Site

City

Warminster

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01338 Boehringer Ingelheim Investigational Site

City

Wyomissing

State/Province

Pennsylvania

Country

United States

Facility Name

205.452.01267 Boehringer Ingelheim Investigational Site

City

Cranston

State/Province

Rhode Island

Country

United States

Facility Name

205.452.01214 Boehringer Ingelheim Investigational Site

City

Johnston

State/Province

Rhode Island

Country

United States

Facility Name

205.452.01340 Boehringer Ingelheim Investigational Site

City

Anderson

State/Province

South Carolina

Country

United States

Facility Name

205.452.01066 Boehringer Ingelheim Investigational Site

City

Charleston

State/Province

South Carolina

Country

United States

Facility Name

205.452.01217 Boehringer Ingelheim Investigational Site

City

Columbia

State/Province

South Carolina

Country

United States

Facility Name

205.452.01303 Boehringer Ingelheim Investigational Site

City

Easley

State/Province

South Carolina

Country

United States

Facility Name

205.452.01259 Boehringer Ingelheim Investigational Site

City

Florence

State/Province

South Carolina

Country

United States

Facility Name

205.452.01013 Boehringer Ingelheim Investigational Site

City

Gaffney

State/Province

South Carolina

Country

United States

Facility Name

205.452.01077 Boehringer Ingelheim Investigational Site

City

Greenville

State/Province

South Carolina

Country

United States

Facility Name

205.452.01093 Boehringer Ingelheim Investigational Site

City

Greer

State/Province

South Carolina

Country

United States

Facility Name

205.452.01295 Boehringer Ingelheim Investigational Site

City

Hodges

State/Province

South Carolina

Country

United States

Facility Name

205.452.01335 Boehringer Ingelheim Investigational Site

City

Myrtle Beach

State/Province

South Carolina

Country

United States

Facility Name

205.452.01056 Boehringer Ingelheim Investigational Site

City

Rock Hill

State/Province

South Carolina

Country

United States

Facility Name

205.452.01294 Boehringer Ingelheim Investigational Site

City

Spartanburg

State/Province

South Carolina

Country

United States

Facility Name

205.452.01004 Boehringer Ingelheim Investigational Site

City

Rapid City

State/Province

South Dakota

Country

United States

Facility Name

205.452.01126 Boehringer Ingelheim Investigational Site

City

Brentwood

State/Province

Tennessee

Country

United States

Facility Name

205.452.01220 Boehringer Ingelheim Investigational Site

City

Chattanooga

State/Province

Tennessee

Country

United States

Facility Name

205.452.01324 Boehringer Ingelheim Investigational Site

City

Chattanooga

State/Province

Tennessee

Country

United States

Facility Name

205.452.01342 Boehringer Ingelheim Investigational Site

City

Kingsport

State/Province

Tennessee

Country

United States

Facility Name

205.452.01096 Boehringer Ingelheim Investigational Site

City

Arlington

State/Province

Texas

Country

United States

Facility Name

205.452.01050 Boehringer Ingelheim Investigational Site

City

Corsicana

State/Province

Texas

Country

United States

Facility Name

205.452.01233 Boehringer Ingelheim Investigational Site

City

Dallas

State/Province

Texas

Country

United States

Facility Name

205.452.01334 Boehringer Ingelheim Investigational Site

City

Dallas

State/Province

Texas

Country

United States

Facility Name

205.452.01057 Boehringer Ingelheim Investigational Site

City

Fort Worth

State/Province

Texas

Country

United States

Facility Name

205.452.01181 Boehringer Ingelheim Investigational Site

City

Fort Worth

State/Province

Texas

Country

United States

Facility Name

205.452.01272 Boehringer Ingelheim Investigational Site

City

Fort Worth

State/Province

Texas

Country

United States

Facility Name

205.452.01082 Boehringer Ingelheim Investigational Site

City

Houston

State/Province

Texas

Country

United States

Facility Name

205.452.01105 Boehringer Ingelheim Investigational Site

City

Houston

State/Province

Texas

Country

United States

Facility Name

205.452.01178 Boehringer Ingelheim Investigational Site

City

Houston

State/Province

Texas

Country

United States

Facility Name

205.452.01212 Boehringer Ingelheim Investigational Site

City

Houston

State/Province

Texas

Country

United States

Facility Name

205.452.01274 Boehringer Ingelheim Investigational Site

City

Longview

State/Province

Texas

Country

United States

Facility Name

205.452.01116 Boehringer Ingelheim Investigational Site

City

McKinney

State/Province

Texas

Country

United States

Facility Name

205.452.01262 Boehringer Ingelheim Investigational Site

City

Richardson

State/Province

Texas

Country

United States

Facility Name

205.452.01055 Boehringer Ingelheim Investigational Site

City

San Antonio

State/Province

Texas

Country

United States

Facility Name

205.452.01182 Boehringer Ingelheim Investigational Site

City

San Antonio

State/Province

Texas

Country

United States

Facility Name

205.452.01186 Boehringer Ingelheim Investigational Site

City

San Antonio

State/Province

Texas

Country

United States

Facility Name

205.452.01353 Boehringer Ingelheim Investigational Site

City

San Antonio

State/Province

Texas

Country

United States

Facility Name

205.452.01215 Boehringer Ingelheim Investigational Site

City

Sugar Land

State/Province

Texas

Country

United States

Facility Name

205.452.01223 Boehringer Ingelheim Investigational Site

City

Midvale

State/Province

Utah

Country

United States

Facility Name

205.452.01001 Boehringer Ingelheim Investigational Site

City

Salt Lake City

State/Province

Utah

Country

United States

Facility Name

205.452.01079 Boehringer Ingelheim Investigational Site

City

Abingdon

State/Province

Virginia

Country

United States

Facility Name

205.452.01234 Boehringer Ingelheim Investigational Site

City

Alexandria

State/Province

Virginia

Country

United States

Facility Name

205.452.01065 Boehringer Ingelheim Investigational Site

City

Danville

State/Province

Virginia

Country

United States

Facility Name

205.452.01285 Boehringer Ingelheim Investigational Site

City

Danville

State/Province

Virginia

Country

United States

Facility Name

205.452.01045 Boehringer Ingelheim Investigational Site

City

Ettrick

State/Province

Virginia

Country

United States

Facility Name

205.452.01030 Boehringer Ingelheim Investigational Site

City

Lynchburg

State/Province

Virginia

Country

United States

Facility Name

205.452.01016 Boehringer Ingelheim Investigational Site

City

Richmond

State/Province

Virginia

Country

United States

Facility Name

205.452.01039 Boehringer Ingelheim Investigational Site

City

Richmond

State/Province

Virginia

Country

United States

Facility Name

205.452.01044 Boehringer Ingelheim Investigational Site

City

Richmond

State/Province

Virginia

Country

United States

Facility Name

205.452.01300 Boehringer Ingelheim Investigational Site

City

Richmond

State/Province

Virginia

Country

United States

Facility Name

205.452.01099 Boehringer Ingelheim Investigational Site

City

Selah

State/Province

Washington

Country

United States

Facility Name

205.452.01008 Boehringer Ingelheim Investigational Site

City

Spokane

State/Province

Washington

Country

United States

Facility Name

205.452.01069 Boehringer Ingelheim Investigational Site

City

Spokane

State/Province

Washington

Country

United States

Facility Name

205.452.01145 Boehringer Ingelheim Investigational Site

City

Spokane

State/Province

Washington

Country

United States

Facility Name

205.452.01185 Boehringer Ingelheim Investigational Site

City

Tacoma

State/Province

Washington

Country

United States

Facility Name

205.452.01007 Boehringer Ingelheim Investigational Site

City

Wenatchee

State/Province

Washington

Country

United States

Facility Name

205.452.01201 Boehringer Ingelheim Investigational Site

City

Oregon

State/Province

Wisconsin

Country

United States

Facility Name

205.452.01344 Boehringer Ingelheim Investigational Site

City

West Allis

State/Province

Wisconsin

Country

United States

Facility Name

205.452.54003 Boehringer Ingelheim Investigational Site

City

Capital Federal

Country

Argentina

Facility Name

205.452.54011 Boehringer Ingelheim Investigational Site

City

Capital Federal

Country

Argentina

Facility Name

205.452.54013 Boehringer Ingelheim Investigational Site

City

Capital Federal

Country

Argentina

Facility Name

205.452.54027 Boehringer Ingelheim Investigational Site

City

Capital Federal

Country

Argentina

Facility Name

205.452.54029 Boehringer Ingelheim Investigational Site

City

Capital Federal

Country

Argentina

Facility Name

205.452.54031 Boehringer Ingelheim Investigational Site

City

Capital Federal

Country

Argentina

Facility Name

205.452.54025 Boehringer Ingelheim Investigational Site

City

Florencio Varela

Country

Argentina

Facility Name

205.452.54007 Boehringer Ingelheim Investigational Site

City

Mar del Plata

Country

Argentina

Facility Name

205.452.54015 Boehringer Ingelheim Investigational Site

City

Mar del Plata

Country

Argentina

Facility Name

205.452.54001 Boehringer Ingelheim Investigational Site

City

Mendoza

Country

Argentina

Facility Name

205.452.54019 Boehringer Ingelheim Investigational Site

City

Monte Grande

Country

Argentina

Facility Name

205.452.54005 Boehringer Ingelheim Investigational Site

City

Quilmes

Country

Argentina

Facility Name

205.452.54009 Boehringer Ingelheim Investigational Site

City

Rosario

Country

Argentina

Facility Name

205.452.54021 Boehringer Ingelheim Investigational Site

City

Rosario

Country

Argentina

Facility Name

205.452.54017 Boehringer Ingelheim Investigational Site

City

San Miguel de Tucumán

Country

Argentina

Facility Name

205.452.54023 Boehringer Ingelheim Investigational Site

City

San Miguel de Tucumán

Country

Argentina

Facility Name

205.452.61006 Boehringer Ingelheim Investigational Site

City

Adelaide

State/Province

South Australia

Country

Australia

Facility Name

205.452.61002 Boehringer Ingelheim Investigational Site

City

Woodville

State/Province

South Australia

Country

Australia

Facility Name

205.452.61004 Boehringer Ingelheim Investigational Site

City

Box Hill

State/Province

Victoria

Country

Australia

Facility Name

205.452.61003 Boehringer Ingelheim Investigational Site

City

Footscray

State/Province

Victoria

Country

Australia

Facility Name

205.452.61001 Boehringer Ingelheim Investigational Site

City

Frankston

State/Province

Victoria

Country

Australia

Facility Name

205.452.61005 Boehringer Ingelheim Investigational Site

City

Nedlands

State/Province

Western Australia

Country

Australia

Facility Name

205.452.43002 Boehringer Ingelheim Investigational Site

City

Feldbach

Country

Austria

Facility Name

205.452.43003 Boehringer Ingelheim Investigational Site

City

Hallein

Country

Austria

Facility Name

205.452.43005 Boehringer Ingelheim Investigational Site

City

Thalheim bei Wels

Country

Austria

Facility Name

205.452.32009 Boehringer Ingelheim Investigational Site

City

Godinne

Country

Belgium

Facility Name

205.452.32007 Boehringer Ingelheim Investigational Site

City

Gozée

Country

Belgium

Facility Name

205.452.32002 Boehringer Ingelheim Investigational Site

City

Halen

Country

Belgium

Facility Name

205.452.32001 Boehringer Ingelheim Investigational Site

City

Leuven

Country

Belgium

Facility Name

205.452.32006 Boehringer Ingelheim Investigational Site

City

Linkebeek

Country

Belgium

Facility Name

205.452.32005 Boehringer Ingelheim Investigational Site

City

Merksem

Country

Belgium

Facility Name

205.452.32008 Boehringer Ingelheim Investigational Site

City

Natoye

Country

Belgium

Facility Name

205.452.32003 Boehringer Ingelheim Investigational Site

City

Tessenderlo

Country

Belgium

Facility Name

205.452.32004 Boehringer Ingelheim Investigational Site

City

Zichem

Country

Belgium

Facility Name

205.452.55005 Boehringer Ingelheim Investigational Site

City

Florianópolis

Country

Brazil

Facility Name

205.452.55010 Boehringer Ingelheim Investigational Site

City

Passo Fundo - RS

Country

Brazil

Facility Name

205.452.55001 Boehringer Ingelheim Investigational Site

City

Porto Alegre

Country

Brazil

Facility Name

205.452.55002 Boehringer Ingelheim Investigational Site

City

Porto Alegre

Country

Brazil

Facility Name

205.452.55003 Boehringer Ingelheim Investigational Site

City

Recife

Country

Brazil

Facility Name

205.452.55004 Boehringer Ingelheim Investigational Site

City

Rio de Janeiro

Country

Brazil

Facility Name

205.452.55011 Boehringer Ingelheim Investigational Site

City

Río de Janeiro

Country

Brazil

Facility Name

205.452.55008 Boehringer Ingelheim Investigational Site

City

Sao Pablo

Country

Brazil

Facility Name

205.452.55009 Boehringer Ingelheim Investigational Site

City

Sao Paulo

Country

Brazil

Facility Name

205.452.55006 Boehringer Ingelheim Investigational Site

City

São Paulo

Country

Brazil

Facility Name

205.452.55007 Boehringer Ingelheim Investigational Site

City

São Paulo

Country

Brazil

Facility Name

205.452.35909 Boehringer Ingelheim Investigational Site

City

Plovdiv

Country

Bulgaria

Facility Name

205.452.35910 Boehringer Ingelheim Investigational Site

City

Plovdiv

Country

Bulgaria

Facility Name

205.452.35901 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35902 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35903 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35904 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35905 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35908 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35914 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35915 Boehringer Ingelheim Investigational Site

City

Sofia

Country

Bulgaria

Facility Name

205.452.35912 Boehringer Ingelheim Investigational Site

City

Stara Zagora

Country

Bulgaria

Facility Name

205.452.35906 Boehringer Ingelheim Investigational Site

City

Veliko Turnovo

Country

Bulgaria

Facility Name

205.452.11015 Boehringer Ingelheim Investigational Site

City

Calgary

State/Province

Alberta

Country

Canada

Facility Name

205.452.11032 Boehringer Ingelheim Investigational Site

City

Calgary

State/Province

Alberta

Country

Canada

Facility Name

205.452.11028 Boehringer Ingelheim Investigational Site

City

Edmonton

State/Province

Alberta

Country

Canada

Facility Name

205.452.11037 Boehringer Ingelheim Investigational Site

City

Edmonton

State/Province

Alberta

Country

Canada

Facility Name

205.452.11045 Boehringer Ingelheim Investigational Site

City

Edmonton

State/Province

Alberta

Country

Canada

Facility Name

205.452.11047 Boehringer Ingelheim Investigational Site

City

Edmonton

State/Province

Alberta

Country

Canada

Facility Name

205.452.11002 Boehringer Ingelheim Investigational Site

City

Spruce Grove

State/Province

Alberta

Country

Canada

Facility Name

205.452.11048 Boehringer Ingelheim Investigational Site

City

Kelowna

State/Province

British Columbia

Country

Canada

Facility Name

205.452.11051 Boehringer Ingelheim Investigational Site

City

Maple Ridge

State/Province

British Columbia

Country

Canada

Facility Name

205.452.11014 Boehringer Ingelheim Investigational Site

City

Vancouver

State/Province

British Columbia

Country

Canada

Facility Name

205.452.11016 Boehringer Ingelheim Investigational Site

City

Vancouver

State/Province

British Columbia

Country

Canada

Facility Name

205.452.11025 Boehringer Ingelheim Investigational Site

City

Winnipeg

State/Province

Manitoba

Country

Canada

Facility Name

205.452.11033 Boehringer Ingelheim Investigational Site

City

Moncton

State/Province

New Brunswick

Country

Canada

Facility Name

205.452.11010 Boehringer Ingelheim Investigational Site

City

Saint John

State/Province

New Brunswick

Country

Canada

Facility Name

205.452.11044 Boehringer Ingelheim Investigational Site

City

Grand Falls-Windsor

State/Province

Newfoundland and Labrador

Country

Canada

Facility Name

205.452.11053 Boehringer Ingelheim Investigational Site

City

Mount Pearl

State/Province

Newfoundland and Labrador

Country

Canada

Facility Name

205.452.11017 Boehringer Ingelheim Investigational Site

City

St. John's

State/Province

Newfoundland and Labrador

Country

Canada

Facility Name

205.452.11021 Boehringer Ingelheim Investigational Site

City

St. John's

State/Province

Newfoundland and Labrador

Country

Canada

Facility Name

205.452.11030 Boehringer Ingelheim Investigational Site

City

Burlington

State/Province

Ontario

Country

Canada

Facility Name

205.452.11042 Boehringer Ingelheim Investigational Site

City

Corunna

State/Province

Ontario

Country

Canada

Facility Name

205.452.11049 Boehringer Ingelheim Investigational Site

City

Courtice

State/Province

Ontario

Country

Canada

Facility Name

205.452.11004 Boehringer Ingelheim Investigational Site

City

Downsview

State/Province

Ontario

Country

Canada

Facility Name

205.452.11009 Boehringer Ingelheim Investigational Site

City

Hamilton

State/Province

Ontario

Country

Canada

Facility Name

205.452.11029 Boehringer Ingelheim Investigational Site

City

Hamilton

State/Province

Ontario

Country

Canada

Facility Name

205.452.11050 Boehringer Ingelheim Investigational Site

City

Hamilton

State/Province

Ontario

Country

Canada

Facility Name

205.452.11040 Boehringer Ingelheim Investigational Site

City

Kingston

State/Province

Ontario

Country

Canada

Facility Name

205.452.11035 Boehringer Ingelheim Investigational Site

City

London

State/Province

Ontario

Country

Canada

Facility Name

205.452.11001 Boehringer Ingelheim Investigational Site

City

Mississauga

State/Province

Ontario

Country

Canada

Facility Name

205.452.11054 Boehringer Ingelheim Investigational Site

City

Mississauga

State/Province

Ontario

Country

Canada

Facility Name

205.452.11022 Boehringer Ingelheim Investigational Site

City

Newmarket

State/Province

Ontario

Country

Canada

Facility Name

205.452.11024 Boehringer Ingelheim Investigational Site

City

Ottawa

State/Province

Ontario

Country

Canada

Facility Name

205.452.11027 Boehringer Ingelheim Investigational Site

City

Richmond Hill

State/Province

Ontario

Country

Canada

Facility Name

205.452.11041 Boehringer Ingelheim Investigational Site

City

Sarnia

State/Province

Ontario

Country

Canada

Facility Name

205.452.11019 Boehringer Ingelheim Investigational Site

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

205.452.11034 Boehringer Ingelheim Investigational Site

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

205.452.11052 Boehringer Ingelheim Investigational Site

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

205.452.11012 Boehringer Ingelheim Investigational Site

City

Windsor

State/Province

Ontario

Country

Canada

Facility Name

205.452.11007 Boehringer Ingelheim Investigational Site

City

Greenfield Park

State/Province

Quebec

Country

Canada

Facility Name

205.452.11005 Boehringer Ingelheim Investigational Site

City

La Malbaie

State/Province

Quebec

Country

Canada

Facility Name

205.452.11006 Boehringer Ingelheim Investigational Site

City

Longueuil

State/Province

Quebec

Country

Canada

Facility Name

205.452.11043 Boehringer Ingelheim Investigational Site

City

Montreal

State/Province

Quebec

Country

Canada

Facility Name

205.452.11013 Boehringer Ingelheim Investigational Site

City

Point Claire

State/Province

Quebec

Country

Canada

Facility Name

205.452.11018 Boehringer Ingelheim Investigational Site

City

Sherbrooke

State/Province

Quebec

Country

Canada

Facility Name

205.452.11020 Boehringer Ingelheim Investigational Site

City

St. Lambert

State/Province

Quebec

Country

Canada

Facility Name

205.452.11026 Boehringer Ingelheim Investigational Site

City

Trois-Rivieres

State/Province

Quebec

Country

Canada

Facility Name

205.452.11003 Boehringer Ingelheim Investigational Site

City

Saskatoon

State/Province

Saskatchewan

Country

Canada

Facility Name

205.452.11011 Boehringer Ingelheim Investigational Site

City

Saskatoon

State/Province

Saskatchewan

Country

Canada

Facility Name

205.452.11036 Boehringer Ingelheim Investigational Site

City

Saskatoon

State/Province

Saskatchewan

Country

Canada

Facility Name

205.452.11039 Boehringer Ingelheim Investigational Site

City

Saskatoon

State/Province

Saskatchewan

Country

Canada

Facility Name

205.452.11031 Boehringer Ingelheim Investigational Site

City

Quebec

Country

Canada

Facility Name

205.452.86009 Boehringer Ingelheim Investigational Site

City

Beijing

Country

China

Facility Name

205.452.86010 Boehringer Ingelheim Investigational Site

City

Beijing

Country

China

Facility Name

205.452.86011 Boehringer Ingelheim Investigational Site

City

Beijing

Country

China

Facility Name

205.452.86012 Boehringer Ingelheim Investigational Site

City

Beijing

Country

China

Facility Name

205.452.86038 Boehringer Ingelheim Investigational Site

City

Beijing

Country

China

Facility Name

205.452.86026 Boehringer Ingelheim Investigational Site

City

Changchun

Country

China

Facility Name

205.452.86024 Boehringer Ingelheim Investigational Site

City

Changsha

Country

China

Facility Name

205.452.86025 Boehringer Ingelheim Investigational Site

City

Changsha

Country

China

Facility Name

205.452.86021 Boehringer Ingelheim Investigational Site

City

Chengdu

Country

China

Facility Name

205.452.86032 Boehringer Ingelheim Investigational Site

City

Chengdu

Country

China

Facility Name

205.452.86034 Boehringer Ingelheim Investigational Site

City

Chongqing

Country

China

Facility Name

205.452.86035 Boehringer Ingelheim Investigational Site

City

Chongqing

Country

China

Facility Name

205.452.86036 Boehringer Ingelheim Investigational Site

City

Chongqing

Country

China

Facility Name

205.452.86020 Boehringer Ingelheim Investigational Site

City

Foshan

Country

China

Facility Name

205.452.86001 Boehringer Ingelheim Investigational Site

City

Guangzhou

Country

China

Facility Name

205.452.86004 Boehringer Ingelheim Investigational Site

City

Guangzhou

Country

China

Facility Name

205.452.86005 Boehringer Ingelheim Investigational Site

City

Guangzhou

Country

China

Facility Name

205.452.86019 Boehringer Ingelheim Investigational Site

City

Guangzhou

Country

China

Facility Name

205.452.86028 Boehringer Ingelheim Investigational Site

City

Guangzhou

Country

China

Facility Name

205.452.86030 Boehringer Ingelheim Investigational Site

City

Haikou

Country

China

Facility Name

205.452.86007 Boehringer Ingelheim Investigational Site

City

Hangzhou

Country

China

Facility Name

205.452.86008 Boehringer Ingelheim Investigational Site

City

Hangzhou

Country

China

Facility Name

205.452.86029 Boehringer Ingelheim Investigational Site

City

Nan Ning

Country

China

Facility Name

205.452.86037 Boehringer Ingelheim Investigational Site

City

Nanchang

Country

China

Facility Name

205.452.86022 Boehringer Ingelheim Investigational Site

City

Nanjing

Country

China

Facility Name

205.452.86027 Boehringer Ingelheim Investigational Site

City

Qingdao

Country

China

Facility Name

205.452.86002 Boehringer Ingelheim Investigational Site

City

Shanghai

Country

China

Facility Name

205.452.86003 Boehringer Ingelheim Investigational Site

City

Shanghai

Country

China

Facility Name

205.452.86018 Boehringer Ingelheim Investigational Site

City

Shanghai

Country

China

Facility Name

205.452.86014 Boehringer Ingelheim Investigational Site

City

Shenyang

Country

China

Facility Name

205.452.86015 Boehringer Ingelheim Investigational Site

City

Shenyang

Country

China

Facility Name

205.452.86006 Boehringer Ingelheim Investigational Site

City

Suzhou

Country

China

Facility Name

205.452.86033 Boehringer Ingelheim Investigational Site

City

Tianjin

Country

China

Facility Name

205.452.86031 Boehringer Ingelheim Investigational Site

City

Wuhan

Country

China

Facility Name

205.452.86016 Boehringer Ingelheim Investigational Site

City

Xi'An

Country

China

Facility Name

205.452.86017 Boehringer Ingelheim Investigational Site

City

Xi'An

Country

China

Facility Name

205.452.57002 Boehringer Ingelheim Investigational Site

City

Bogotá

Country

Colombia

Facility Name

205.452.57004 Boehringer Ingelheim Investigational Site

City

Bogotá

Country

Colombia

Facility Name

205.452.57005 Boehringer Ingelheim Investigational Site

City

Bogotá

Country

Colombia

Facility Name

205.452.57006 Boehringer Ingelheim Investigational Site

City

Bogotá

Country

Colombia

Facility Name

205.452.57001 Boehringer Ingelheim Investigational Site

City

Medellín

Country

Colombia

Facility Name

205.452.38512 Boehringer Ingelheim Investigational Site

City

Cakovec

Country

Croatia

Facility Name

205.452.38508 Boehringer Ingelheim Investigational Site

City

Dubrovnik

Country

Croatia

Facility Name

205.452.38510 Boehringer Ingelheim Investigational Site

City

Osijek

Country

Croatia

Facility Name

205.452.38501 Boehringer Ingelheim Investigational Site

City

Rijeka

Country

Croatia

Facility Name

205.452.38506 Boehringer Ingelheim Investigational Site

City

Sisak

Country

Croatia

Facility Name

205.452.38502 Boehringer Ingelheim Investigational Site

City

Split

Country

Croatia

Facility Name

205.452.38503 Boehringer Ingelheim Investigational Site

City

Split

Country

Croatia

Facility Name

205.452.38504 Boehringer Ingelheim Investigational Site

City

Zagreb

Country

Croatia

Facility Name

205.452.38505 Boehringer Ingelheim Investigational Site

City

Zagreb

Country

Croatia

Facility Name

205.452.38507 Boehringer Ingelheim Investigational Site

City

Zagreb

Country

Croatia

Facility Name

205.452.38509 Boehringer Ingelheim Investigational Site

City

Zagreb

Country

Croatia

Facility Name

205.452.38511 Boehringer Ingelheim Investigational Site

City

Zagreb

Country

Croatia

Facility Name

205.452.45002 Boehringer Ingelheim Investigational Site

City

Aalborg

Country

Denmark

Facility Name

205.452.45003 Boehringer Ingelheim Investigational Site

City

Aarhus C

Country

Denmark

Facility Name

205.452.45006 Boehringer Ingelheim Investigational Site

City

Birkerød

Country

Denmark

Facility Name

205.452.45013 Boehringer Ingelheim Investigational Site

City

Kolding

Country

Denmark

Facility Name

205.452.45001 Boehringer Ingelheim Investigational Site

City

København NV

Country

Denmark

Facility Name

205.452.45005 Boehringer Ingelheim Investigational Site

City

København S

Country

Denmark

Facility Name

205.452.45012 Boehringer Ingelheim Investigational Site

City

Odense C

Country

Denmark

Facility Name

205.452.45016 Boehringer Ingelheim Investigational Site

City

Roskilde

Country

Denmark

Facility Name

205.452.45009 Boehringer Ingelheim Investigational Site

City

Rødovre

Country

Denmark

Facility Name

205.452.45010 Boehringer Ingelheim Investigational Site

City

Rødovre

Country

Denmark

Facility Name

205.452.45004 Boehringer Ingelheim Investigational Site

City

Silkeborg

Country

Denmark

Facility Name

205.452.45014 Boehringer Ingelheim Investigational Site

City

Skive

Country

Denmark

Facility Name

205.452.45011 Boehringer Ingelheim Investigational Site

City

Sønderborg

Country

Denmark

Facility Name

205.452.45015 Boehringer Ingelheim Investigational Site

City

Viby

Country

Denmark

Facility Name

205.452.45007 Boehringer Ingelheim Investigational Site

City

Værløse

Country

Denmark

Facility Name

205.452.35801 Boehringer Ingelheim Investigational Site

City

Helsinki

Country

Finland

Facility Name

205.452.35804 Boehringer Ingelheim Investigational Site

City

Lahti

Country

Finland

Facility Name

205.452.35808 Boehringer Ingelheim Investigational Site

City

Pori

Country

Finland

Facility Name

205.452.35805 Boehringer Ingelheim Investigational Site

City

Porvoo

Country

Finland

Facility Name

205.452.35806 Boehringer Ingelheim Investigational Site

City

Tammisaari

Country

Finland

Facility Name

205.452.35802 Boehringer Ingelheim Investigational Site

City

Tampere

Country

Finland

Facility Name

205.452.35803 Boehringer Ingelheim Investigational Site

City

Turku

Country

Finland

Facility Name

205.452.33087 Boehringer Ingelheim Investigational Site

City

Albens

Country

France

Facility Name

205.452.33028 Boehringer Ingelheim Investigational Site

City

Angers

Country

France

Facility Name

205.452.33055 Boehringer Ingelheim Investigational Site

City

Angers

Country

France

Facility Name

205.452.33142 Boehringer Ingelheim Investigational Site

City

Angers

Country

France

Facility Name

205.452.33159 Boehringer Ingelheim Investigational Site

City

Angers

Country

France

Facility Name

205.452.33030 Boehringer Ingelheim Investigational Site

City

Anzin

Country

France

Facility Name

205.452.33158 Boehringer Ingelheim Investigational Site

City

Arras

Country

France

Facility Name

205.452.33084 Boehringer Ingelheim Investigational Site

City

Avrillé

Country

France

Facility Name

205.452.33128 Boehringer Ingelheim Investigational Site

City

Becon les Granits

Country

France

Facility Name

205.452.33029 Boehringer Ingelheim Investigational Site

City

Bersée

Country

France

Facility Name

205.452.33018 Boehringer Ingelheim Investigational Site

City

Beziers

Country

France

Facility Name

205.452.33053 Boehringer Ingelheim Investigational Site

City

Bischheim

Country

France

Facility Name

205.452.33024 Boehringer Ingelheim Investigational Site

City

Blois

Country

France

Facility Name

205.452.33043 Boehringer Ingelheim Investigational Site

City

Bort les Orgues

Country

France

Facility Name

205.452.33091 Boehringer Ingelheim Investigational Site

City

Bourg des cptes

Country

France

Facility Name

205.452.33123 Boehringer Ingelheim Investigational Site

City

Briollay

Country

France

Facility Name

205.452.33063 Boehringer Ingelheim Investigational Site

City

Broglie

Country

France

Facility Name

205.452.33074 Boehringer Ingelheim Investigational Site

City

Bruay La Buissiere

Country

France

Facility Name

205.452.33010 Boehringer Ingelheim Investigational Site

City

Cannes Cedex

Country

France

Facility Name

205.452.33118 Boehringer Ingelheim Investigational Site

City

Cannes

Country

France

Facility Name

205.452.33009 Boehringer Ingelheim Investigational Site

City

Chamalières

Country

France

Facility Name

205.452.33073 Boehringer Ingelheim Investigational Site

City

Chambery

Country

France

Facility Name

205.452.33059 Boehringer Ingelheim Investigational Site

City

Chateau Renault

Country

France

Facility Name

205.452.33089 Boehringer Ingelheim Investigational Site

City

Colombey les Belles

Country

France

Facility Name

205.452.33099 Boehringer Ingelheim Investigational Site

City

Cournonterral

Country

France

Facility Name

205.452.33127 Boehringer Ingelheim Investigational Site

City

Cournonterral

Country

France

Facility Name

205.452.33162 Boehringer Ingelheim Investigational Site

City

Croix

Country

France

Facility Name

205.452.33105 Boehringer Ingelheim Investigational Site

City

Dinard

Country

France

Facility Name

205.452.33110 Boehringer Ingelheim Investigational Site

City

Donges

Country

France

Facility Name

205.452.33094 Boehringer Ingelheim Investigational Site

City

Gambsheim

Country

France

Facility Name

205.452.33046 Boehringer Ingelheim Investigational Site

City

Grenoble

Country

France

Facility Name

205.452.33096 Boehringer Ingelheim Investigational Site

City

Hautmont

Country

France

Facility Name

205.452.33090 Boehringer Ingelheim Investigational Site

City

Hinx

Country

France

Facility Name

205.452.33145 Boehringer Ingelheim Investigational Site

City

Jarny

Country

France

Facility Name

205.452.33154 Boehringer Ingelheim Investigational Site

City

La Bouëxière

Country

France

Facility Name

205.452.33065 Boehringer Ingelheim Investigational Site

City

La Chapelle sur Erdre

Country

France

Facility Name

205.452.33102 Boehringer Ingelheim Investigational Site

City

La Montagne

Country

France

Facility Name

205.452.33100 Boehringer Ingelheim Investigational Site

City

La Riche

Country

France

Facility Name

205.452.33058 Boehringer Ingelheim Investigational Site

City

Lambersart

Country

France

Facility Name

205.452.33098 Boehringer Ingelheim Investigational Site

City

Lambersart

Country

France

Facility Name

205.452.33103 Boehringer Ingelheim Investigational Site

City

Levallois Perret

Country

France

Facility Name

205.452.33164 Boehringer Ingelheim Investigational Site

City

Louvigne De bais

Country

France

Facility Name

205.452.33111 Boehringer Ingelheim Investigational Site

City

Luynes

Country

France

Facility Name

205.452.33136 Boehringer Ingelheim Investigational Site

City

Marcq en Baroeul

Country

France

Facility Name

205.452.33115 Boehringer Ingelheim Investigational Site

City

Mondelange

Country

France

Facility Name

205.452.33088 Boehringer Ingelheim Investigational Site

City

Mont de Marsan

Country

France

Facility Name

205.452.33138 Boehringer Ingelheim Investigational Site

City

Mont de Marsan

Country

France

Facility Name

205.452.33005 Boehringer Ingelheim Investigational Site

City

Montigny les Metz

Country

France

Facility Name

205.452.33163 Boehringer Ingelheim Investigational Site

City

Mundolsheim

Country

France

Facility Name

205.452.33109 Boehringer Ingelheim Investigational Site

City

Murs Erigne

Country

France

Facility Name

205.452.33031 Boehringer Ingelheim Investigational Site

City

Nantes

Country

France

Facility Name

205.452.33003 Boehringer Ingelheim Investigational Site

City

Nice

Country

France

Facility Name

205.452.33108 Boehringer Ingelheim Investigational Site

City

Oignies

Country

France

Facility Name

205.452.33014 Boehringer Ingelheim Investigational Site

City

Ollioules

Country

France

Facility Name

205.452.33157 Boehringer Ingelheim Investigational Site

City

Orthez

Country

France

Facility Name

205.452.33112 Boehringer Ingelheim Investigational Site

City

Parcay les Pins

Country

France

Facility Name

205.452.33001 Boehringer Ingelheim Investigational Site

City

Paris

Country

France

Facility Name

205.452.33051 Boehringer Ingelheim Investigational Site

City

Paris

Country

France

Facility Name

205.452.33082 Boehringer Ingelheim Investigational Site

City

Paris

Country

France

Facility Name

205.452.33165 Boehringer Ingelheim Investigational Site

City

Paris

Country

France

Facility Name

205.452.33130 Boehringer Ingelheim Investigational Site

City

Pont à Mousson

Country

France

Facility Name

205.452.33122 Boehringer Ingelheim Investigational Site

City

Quarouble

Country

France

Facility Name

205.452.33006 Boehringer Ingelheim Investigational Site

City

Reims

Country

France

Facility Name

205.452.33153 Boehringer Ingelheim Investigational Site

City

Rosiers d'Egletons

Country

France

Facility Name

205.452.33161 Boehringer Ingelheim Investigational Site

City

Rugles

Country

France

Facility Name

205.452.33126 Boehringer Ingelheim Investigational Site

City

Saint Alban Leysse

Country

France

Facility Name

205.452.33140 Boehringer Ingelheim Investigational Site

City

Saint Aulaire

Country

France

Facility Name

205.452.33052 Boehringer Ingelheim Investigational Site

City

Saint Avertin

Country

France

Facility Name

205.452.33011 Boehringer Ingelheim Investigational Site

City

Saint Léger des Bois

Country

France

Facility Name

205.452.33002 Boehringer Ingelheim Investigational Site

City

Saintes

Country

France

Facility Name

205.452.33148 Boehringer Ingelheim Investigational Site

City

Salies de Bearn

Country

France

Facility Name

205.452.33026 Boehringer Ingelheim Investigational Site

City

Savonnières

Country

France

Facility Name

205.452.33067 Boehringer Ingelheim Investigational Site

City

Segre

Country

France

Facility Name

205.452.33040 Boehringer Ingelheim Investigational Site

City

Serres Casset

Country

France

Facility Name

205.452.33012 Boehringer Ingelheim Investigational Site

City

Six Four les Plages

Country

France

Facility Name

205.452.33160 Boehringer Ingelheim Investigational Site

City

St Jouan des Guerets

Country

France

Facility Name

205.452.33079 Boehringer Ingelheim Investigational Site

City

St Sebastien sur Loire

Country

France

Facility Name

205.452.33007 Boehringer Ingelheim Investigational Site

City

Strasbourg

Country

France

Facility Name

205.452.33033 Boehringer Ingelheim Investigational Site

City

Strasbourg

Country

France

Facility Name

205.452.33097 Boehringer Ingelheim Investigational Site

City

Strasbourg

Country

France

Facility Name

205.452.33101 Boehringer Ingelheim Investigational Site

City

Strasbourg

Country

France

Facility Name

205.452.33107 Boehringer Ingelheim Investigational Site

City

Thouars

Country

France

Facility Name

205.452.33116 Boehringer Ingelheim Investigational Site

City

Tinténiac

Country

France

Facility Name

205.452.33013 Boehringer Ingelheim Investigational Site

City

Toulon

Country

France

Facility Name

205.452.33054 Boehringer Ingelheim Investigational Site

City

Tours

Country

France

Facility Name

205.452.33064 Boehringer Ingelheim Investigational Site

City

Tours

Country

France

Facility Name

205.452.33092 Boehringer Ingelheim Investigational Site

City

Tours

Country

France

Facility Name

205.452.33124 Boehringer Ingelheim Investigational Site

City

Tours

Country

France

Facility Name

205.452.33066 Boehringer Ingelheim Investigational Site

City

Vendôme

Country

France

Facility Name

205.452.33137 Boehringer Ingelheim Investigational Site

City

Vernoil

Country

France

Facility Name

205.452.33032 Boehringer Ingelheim Investigational Site

City

Vieux Condé

Country

France

Facility Name

205.452.33151 Boehringer Ingelheim Investigational Site

City

Vihiers

Country

France

Facility Name

205.452.33077 Boehringer Ingelheim Investigational Site

City

Villey St Etienne

Country

France

Facility Name

205.452.33135 Boehringer Ingelheim Investigational Site

City

Wattrelos

Country

France

Facility Name

205.452.99501 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.99502 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.99503 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.99504 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.99505 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.99506 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.99507 Boehringer Ingelheim Investigational Site

City

Tbilisi

Country

Georgia

Facility Name

205.452.49096 Boehringer Ingelheim Investigational Site

City

Aschaffenburg

Country

Germany

Facility Name

205.452.49130 Boehringer Ingelheim Investigational Site

City

Augsburg

Country

Germany

Facility Name

205.452.49161 Boehringer Ingelheim Investigational Site

City

Augsburg

Country

Germany

Facility Name

205.452.49001 Boehringer Ingelheim Investigational Site

City

Backnang

Country

Germany

Facility Name

205.452.49173 Boehringer Ingelheim Investigational Site

City

Bad Kissingen

Country

Germany

Facility Name

205.452.49134 Boehringer Ingelheim Investigational Site

City

Bad Lippspringe

Country

Germany

Facility Name

205.452.49082 Boehringer Ingelheim Investigational Site

City

Bad Neustadt

Country

Germany

Facility Name

205.452.49058 Boehringer Ingelheim Investigational Site

City

Bad Wörishofen

Country

Germany

Facility Name

205.452.49145 Boehringer Ingelheim Investigational Site

City

Bamberg

Country

Germany

Facility Name

205.452.49072 Boehringer Ingelheim Investigational Site

City

Bensheim

Country

Germany

Facility Name

205.452.49048 Boehringer Ingelheim Investigational Site

City

Bergisch Gladbach

Country

Germany

Facility Name

205.452.49006 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49016 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49028 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49031 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49054 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49064 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49066 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49068 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49102 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49135 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49138 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49157 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49167 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49175 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49180 Boehringer Ingelheim Investigational Site

City

Berlin

Country

Germany

Facility Name

205.452.49037 Boehringer Ingelheim Investigational Site

City

Bonn

Country

Germany

Facility Name

205.452.49118 Boehringer Ingelheim Investigational Site

City

Bonn

Country

Germany

Facility Name

205.452.49083 Boehringer Ingelheim Investigational Site

City

Brake

Country

Germany

Facility Name

205.452.49040 Boehringer Ingelheim Investigational Site

City

Bruchsal

Country

Germany

Facility Name

205.452.49089 Boehringer Ingelheim Investigational Site

City

Celle

Country

Germany

Facility Name

205.452.49143 Boehringer Ingelheim Investigational Site

City

Cottbus

Country

Germany

Facility Name

205.452.49119 Boehringer Ingelheim Investigational Site

City

Deggendorf

Country

Germany

Facility Name

205.452.49151 Boehringer Ingelheim Investigational Site

City

Dillingen

Country

Germany

Facility Name

205.452.49117 Boehringer Ingelheim Investigational Site

City

Donaueschingen

Country

Germany

Facility Name

205.452.49015 Boehringer Ingelheim Investigational Site

City

Dortmund

Country

Germany

Facility Name

205.452.49008 Boehringer Ingelheim Investigational Site

City

Düren

Country

Germany

Facility Name

205.452.49098 Boehringer Ingelheim Investigational Site

City

Emden

Country

Germany

Facility Name

205.452.49003 Boehringer Ingelheim Investigational Site

City

Engelskirchen

Country

Germany

Facility Name

205.452.49024 Boehringer Ingelheim Investigational Site

City

Ense

Country

Germany

Facility Name

205.452.49168 Boehringer Ingelheim Investigational Site

City

Essen

Country

Germany

Facility Name

205.452.49104 Boehringer Ingelheim Investigational Site

City

Forchheim

Country

Germany

Facility Name

205.452.49070 Boehringer Ingelheim Investigational Site

City

Frankfurt

Country

Germany

Facility Name

205.452.49147 Boehringer Ingelheim Investigational Site

City

Frankfurt

Country

Germany

Facility Name

205.452.49137 Boehringer Ingelheim Investigational Site

City

Fulda

Country

Germany

Facility Name

205.452.49133 Boehringer Ingelheim Investigational Site

City

Föhren

Country

Germany

Facility Name

205.452.49107 Boehringer Ingelheim Investigational Site

City

Gelnhausen

Country

Germany

Facility Name

205.452.49032 Boehringer Ingelheim Investigational Site

City

Gütersloh

Country

Germany

Facility Name

205.452.49026 Boehringer Ingelheim Investigational Site

City

Hagen

Country

Germany

Facility Name

205.452.49041 Boehringer Ingelheim Investigational Site

City

Hagen

Country

Germany

Facility Name

205.452.49044 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.452.49061 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.452.49080 Boehringer Ingelheim Investigational Site

City

Hamburg

Country

Germany

Facility Name

205.452.49038 Boehringer Ingelheim Investigational Site

City

Hannover

Country

Germany

Facility Name

205.452.49052 Boehringer Ingelheim Investigational Site

City

Hannover

Country

Germany

Facility Name

205.452.49094 Boehringer Ingelheim Investigational Site

City

Hannover

Country

Germany

Facility Name

205.452.49181 Boehringer Ingelheim Investigational Site

City

Heidelberg

Country

Germany

Facility Name

205.452.49116 Boehringer Ingelheim Investigational Site

City

Heilbronn

Country

Germany

Facility Name

205.452.49022 Boehringer Ingelheim Investigational Site

City

Hemmingen

Country

Germany

Facility Name

205.452.49007 Boehringer Ingelheim Investigational Site

City

Höchstädt

Country

Germany

Facility Name

205.452.49136 Boehringer Ingelheim Investigational Site

City

Ingelheim

Country

Germany

Facility Name

205.452.49159 Boehringer Ingelheim Investigational Site

City

Karlsruhe

Country

Germany

Facility Name

205.452.49027 Boehringer Ingelheim Investigational Site

City

Kassel

Country

Germany

Facility Name

205.452.49105 Boehringer Ingelheim Investigational Site

City

Kaufbeuren

Country

Germany

Facility Name

205.452.49101 Boehringer Ingelheim Investigational Site

City

Koblenz

Country

Germany

Facility Name

205.452.49047 Boehringer Ingelheim Investigational Site

City

Käbschütztal-Krögis

Country

Germany

Facility Name

205.452.49146 Boehringer Ingelheim Investigational Site

City

Köln

Country

Germany

Facility Name

205.452.49114 Boehringer Ingelheim Investigational Site

City

Landsberg am Lech

Country

Germany

Facility Name

205.452.49169 Boehringer Ingelheim Investigational Site

City

Langen

Country

Germany

Facility Name

205.452.49017 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.452.49035 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.452.49113 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.452.49139 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.452.49172 Boehringer Ingelheim Investigational Site

City

Leipzig

Country

Germany

Facility Name

205.452.49110 Boehringer Ingelheim Investigational Site

City

Leonberg

Country

Germany

Facility Name

205.452.49088 Boehringer Ingelheim Investigational Site

City

Mannheim

Country

Germany

Facility Name

205.452.49108 Boehringer Ingelheim Investigational Site

City

Marburg

Country

Germany

Facility Name

205.452.49122 Boehringer Ingelheim Investigational Site

City

Marburg

Country

Germany

Facility Name

205.452.49055 Boehringer Ingelheim Investigational Site

City

Minden

Country

Germany

Facility Name

205.452.49025 Boehringer Ingelheim Investigational Site

City

München

Country

Germany

Facility Name

205.452.49131 Boehringer Ingelheim Investigational Site

City

München

Country

Germany

Facility Name

205.452.49023 Boehringer Ingelheim Investigational Site

City

Neumünster

Country

Germany

Facility Name

205.452.49132 Boehringer Ingelheim Investigational Site

City

Neuruppin

Country

Germany

Facility Name

205.452.49045 Boehringer Ingelheim Investigational Site

City

Neuwied

Country

Germany

Facility Name

205.452.49062 Boehringer Ingelheim Investigational Site

City

Oranienburg

Country

Germany

Facility Name

205.452.49124 Boehringer Ingelheim Investigational Site

City

Oschersleben

Country

Germany

Facility Name

205.452.49019 Boehringer Ingelheim Investigational Site

City

Paderborn

Country

Germany

Facility Name

205.452.49053 Boehringer Ingelheim Investigational Site

City

Potsdam

Country

Germany

Facility Name

205.452.49076 Boehringer Ingelheim Investigational Site

City

Potsdam

Country

Germany

Facility Name

205.452.49049 Boehringer Ingelheim Investigational Site

City

Radebeul

Country

Germany

Facility Name

205.452.49056 Boehringer Ingelheim Investigational Site

City

Rathenow

Country

Germany

Facility Name

205.452.49009 Boehringer Ingelheim Investigational Site

City

Raubach

Country

Germany

Facility Name

205.452.49002 Boehringer Ingelheim Investigational Site

City

Rehau

Country

Germany

Facility Name

205.452.49142 Boehringer Ingelheim Investigational Site

City

Reinfeld

Country

Germany

Facility Name

205.452.49030 Boehringer Ingelheim Investigational Site

City

Rhaunen

Country

Germany

Facility Name

205.452.49184 Boehringer Ingelheim Investigational Site

City

Rheine

Country

Germany

Facility Name

205.452.49077 Boehringer Ingelheim Investigational Site

City

Rodgau-Dudenhofen

Country

Germany

Facility Name

205.452.49021 Boehringer Ingelheim Investigational Site

City

Rüsselsheim

Country

Germany

Facility Name

205.452.49091 Boehringer Ingelheim Investigational Site

City

Rüsselsheim

Country

Germany

Facility Name

205.452.49042 Boehringer Ingelheim Investigational Site

City

Saarlouis

Country

Germany

Facility Name

205.452.49034 Boehringer Ingelheim Investigational Site

City

Schwetzingen

Country

Germany

Facility Name

205.452.49013 Boehringer Ingelheim Investigational Site

City

Solingen

Country

Germany

Facility Name

205.452.49057 Boehringer Ingelheim Investigational Site

City

Solingen

Country

Germany

Facility Name

205.452.49078 Boehringer Ingelheim Investigational Site

City

Tübingen

Country

Germany

Facility Name

205.452.49099 Boehringer Ingelheim Investigational Site

City

Ulm

Country

Germany

Facility Name

205.452.49043 Boehringer Ingelheim Investigational Site

City

Wallerfing

Country

Germany

Facility Name

205.452.49067 Boehringer Ingelheim Investigational Site

City

Wardenburg

Country

Germany

Facility Name

205.452.49165 Boehringer Ingelheim Investigational Site

City

Warendorf

Country

Germany

Facility Name

205.452.49051 Boehringer Ingelheim Investigational Site

City

Weinheim

Country

Germany

Facility Name

205.452.49127 Boehringer Ingelheim Investigational Site

City

Weyhe

Country

Germany

Facility Name

205.452.49092 Boehringer Ingelheim Investigational Site

City

Wiesloch

Country

Germany

Facility Name

205.452.49018 Boehringer Ingelheim Investigational Site

City

Witten

Country

Germany

Facility Name

205.452.49029 Boehringer Ingelheim Investigational Site

City

Witten

Country

Germany

Facility Name

205.452.49095 Boehringer Ingelheim Investigational Site

City

Wolfsburg

Country

Germany

Facility Name

205.452.49060 Boehringer Ingelheim Investigational Site

City

Zerbst

Country

Germany

Facility Name

205.452.30002 Boehringer Ingelheim Investigational Site

City

Athens

Country

Greece

Facility Name

205.452.30003 Boehringer Ingelheim Investigational Site

City

Athens

Country

Greece

Facility Name

205.452.30008 Boehringer Ingelheim Investigational Site

City

Athens

Country

Greece

Facility Name

205.452.30001 Boehringer Ingelheim Investigational Site

City

Heraklion

Country

Greece

Facility Name

205.452.30007 Boehringer Ingelheim Investigational Site

City

Kalamaria

Country

Greece

Facility Name

205.452.30010 Boehringer Ingelheim Investigational Site

City

Kavala

Country

Greece

Facility Name

205.452.30012 Boehringer Ingelheim Investigational Site

City

Lamia

Country

Greece

Facility Name

205.452.30005 Boehringer Ingelheim Investigational Site

City

Nafplio

Country

Greece

Facility Name

205.452.30011 Boehringer Ingelheim Investigational Site

City

Rethymno

Country

Greece

Facility Name

205.452.30006 Boehringer Ingelheim Investigational Site

City

Serres

Country

Greece

Facility Name

205.452.30004 Boehringer Ingelheim Investigational Site

City

Thessaloniki

Country

Greece

Facility Name

205.452.30009 Boehringer Ingelheim Investigational Site

City

Thessaloniki

Country

Greece

Facility Name

205.452.50205 Boehringer Ingelheim Investigational Site

City

Guatemala

Country

Guatemala

Facility Name

205.452.50206 Boehringer Ingelheim Investigational Site

City

Guatemala

Country

Guatemala

Facility Name

205.452.50203 Boehringer Ingelheim Investigational Site

City

Nivel 12

Country

Guatemala

Facility Name

205.452.50201 Boehringer Ingelheim Investigational Site

City

Nivel Guatemala

Country

Guatemala

Facility Name

205.452.50202 Boehringer Ingelheim Investigational Site

City

Nivel Guatemala

Country

Guatemala

Facility Name

205.452.50204 Boehringer Ingelheim Investigational Site

City

Nivel Guatemala

Country

Guatemala

Facility Name

205.452.50207 Boehringer Ingelheim Investigational Site

City

Quetzaltenango

Country

Guatemala

Facility Name

205.452.36005 Boehringer Ingelheim Investigational Site

City

Baja

Country

Hungary

Facility Name

205.452.36004 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.452.36016 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.452.36030 Boehringer Ingelheim Investigational Site

City

Budapest

Country

Hungary

Facility Name

205.452.36007 Boehringer Ingelheim Investigational Site

City

Debrecen

Country

Hungary

Facility Name

205.452.36013 Boehringer Ingelheim Investigational Site

City

Debrecen

Country

Hungary

Facility Name

205.452.36015 Boehringer Ingelheim Investigational Site

City

Debrecen

Country

Hungary

Facility Name

205.452.36029 Boehringer Ingelheim Investigational Site

City

Deszk

Country

Hungary

Facility Name

205.452.36026 Boehringer Ingelheim Investigational Site

City

Dombovar

Country

Hungary

Facility Name

205.452.36003 Boehringer Ingelheim Investigational Site

City

Erd

Country

Hungary

Facility Name

205.452.36008 Boehringer Ingelheim Investigational Site

City

Farkasgyepü

Country

Hungary

Facility Name

205.452.36020 Boehringer Ingelheim Investigational Site

City

Györ

Country

Hungary

Facility Name

205.452.36012 Boehringer Ingelheim Investigational Site

City

Hajduböszörmeny

Country

Hungary

Facility Name

205.452.36023 Boehringer Ingelheim Investigational Site

City

Hodmezovasarhely

Country

Hungary

Facility Name

205.452.36010 Boehringer Ingelheim Investigational Site

City

Kaposvar

Country

Hungary

Facility Name

205.452.36018 Boehringer Ingelheim Investigational Site

City

Kapuvar

Country

Hungary

Facility Name

205.452.36002 Boehringer Ingelheim Investigational Site

City

Kecskemet

Country

Hungary

Facility Name

205.452.36001 Boehringer Ingelheim Investigational Site

City

Makó

Country

Hungary

Facility Name

205.452.36006 Boehringer Ingelheim Investigational Site

City

Mohacs

Country

Hungary

Facility Name

205.452.36022 Boehringer Ingelheim Investigational Site

City

Mosonmagyarovar

Country

Hungary

Facility Name

205.452.36027 Boehringer Ingelheim Investigational Site

City

Nagykanizsa

Country

Hungary

Facility Name

205.452.36014 Boehringer Ingelheim Investigational Site

City

Nyiregyhaza

Country

Hungary

Facility Name

205.452.36009 Boehringer Ingelheim Investigational Site

City

Pecs

Country

Hungary

Facility Name

205.452.36011 Boehringer Ingelheim Investigational Site

City

Pecs

Country

Hungary

Facility Name

205.452.36028 Boehringer Ingelheim Investigational Site

City

Siófok

Country

Hungary

Facility Name

205.452.36021 Boehringer Ingelheim Investigational Site

City

Szarvas

Country

Hungary

Facility Name

205.452.36017 Boehringer Ingelheim Investigational Site

City

Szeged

Country

Hungary

Facility Name

205.452.36024 Boehringer Ingelheim Investigational Site

City

Tatabanya

Country

Hungary

Facility Name

205.452.36019 Boehringer Ingelheim Investigational Site

City

Törökbálint

Country

Hungary

Facility Name

205.452.36025 Boehringer Ingelheim Investigational Site

City

Törökbálint

Country

Hungary

Facility Name

205.452.91017 Boehringer Ingelheim Investigational Site

City

Ahmedabad

Country

India

Facility Name

205.452.91018 Boehringer Ingelheim Investigational Site

City

Chennai

Country

India

Facility Name

205.452.91001 Boehringer Ingelheim Investigational Site

City

Coimbatore

Country

India

Facility Name

205.452.91002 Boehringer Ingelheim Investigational Site

City

Coimbatore

Country

India

Facility Name

205.452.91014 Boehringer Ingelheim Investigational Site

City

Dadar(East)

Country

India

Facility Name

205.452.91005 Boehringer Ingelheim Investigational Site

City

Hyderabad

Country

India

Facility Name

205.452.91009 Boehringer Ingelheim Investigational Site

City

Hyderabad

Country

India

Facility Name

205.452.91004 Boehringer Ingelheim Investigational Site

City

Jaipur

Country

India

Facility Name

205.452.91007 Boehringer Ingelheim Investigational Site

City

Jaipur

Country

India

Facility Name

205.452.91015 Boehringer Ingelheim Investigational Site

City

Jaipur

Country

India

Facility Name

205.452.91016 Boehringer Ingelheim Investigational Site

City

Jaipur

Country

India

Facility Name

205.452.91008 Boehringer Ingelheim Investigational Site

City

Karnataka

Country

India

Facility Name

205.452.91006 Boehringer Ingelheim Investigational Site

City

Maharashtra

Country

India

Facility Name

205.452.91003 Boehringer Ingelheim Investigational Site

City

Maharastra

Country

India

Facility Name

205.452.91011 Boehringer Ingelheim Investigational Site

City

Punjab

Country

India

Facility Name

205.452.35307 Boehringer Ingelheim Investigational Site

City

Co. Cork

Country

Ireland

Facility Name

205.452.35306 Boehringer Ingelheim Investigational Site

City

Co. Tipperary

Country

Ireland

Facility Name

205.452.35305 Boehringer Ingelheim Investigational Site

City

Co. Wexford

Country

Ireland

Facility Name

205.452.35301 Boehringer Ingelheim Investigational Site

City

Dublin 24

Country

Ireland

Facility Name

205.452.35302 Boehringer Ingelheim Investigational Site

City

Dublin

Country

Ireland

Facility Name

205.452.35303 Boehringer Ingelheim Investigational Site

City

Limerick

Country

Ireland

Facility Name

205.452.35308 Boehringer Ingelheim Investigational Site

City

Limerick

Country

Ireland

Facility Name

205.452.35304 Boehringer Ingelheim Investigational Site

City

Offaly

Country

Ireland

Facility Name

205.452.97207 Boehringer Ingelheim Investigational Site

City

Ashkelon

Country

Israel

Facility Name

205.452.97204 Boehringer Ingelheim Investigational Site

City

Beer Sheva

Country

Israel

Facility Name

205.452.97208 Boehringer Ingelheim Investigational Site

City

Haifa

Country

Israel

Facility Name

205.452.97202 Boehringer Ingelheim Investigational Site

City

Jerusalem

Country

Israel

Facility Name

205.452.97206 Boehringer Ingelheim Investigational Site

City

Kfar Saba

Country

Israel

Facility Name

205.452.97203 Boehringer Ingelheim Investigational Site

City

Petach Tikva

Country

Israel

Facility Name

205.452.97201 Boehringer Ingelheim Investigational Site

City

Rehovot

Country

Israel

Facility Name

205.452.97205 Boehringer Ingelheim Investigational Site

City

Tel-Aviv

Country

Israel

Facility Name

205.452.39003 Boehringer Ingelheim Investigational Site

City

Arenzano (ge)

Country

Italy

Facility Name

205.452.39019 Boehringer Ingelheim Investigational Site

City

Ascoli Piceno

Country

Italy

Facility Name

205.452.39016 Boehringer Ingelheim Investigational Site

City

Avellino

Country

Italy

Facility Name

205.452.39007 Boehringer Ingelheim Investigational Site

City

Benevento

Country

Italy

Facility Name

205.452.39024 Boehringer Ingelheim Investigational Site

City

Brescia

Country

Italy

Facility Name

205.452.39029 Boehringer Ingelheim Investigational Site

City

Busto Arsizio (va)

Country

Italy

Facility Name

205.452.39011 Boehringer Ingelheim Investigational Site

City

Cagliari

Country

Italy

Facility Name

205.452.39013 Boehringer Ingelheim Investigational Site

City

Cagliari

Country

Italy

Facility Name

205.452.39020 Boehringer Ingelheim Investigational Site

City

Cagliari

Country

Italy

Facility Name

205.452.39015 Boehringer Ingelheim Investigational Site

City

Catanzaro

Country

Italy

Facility Name

205.452.39006 Boehringer Ingelheim Investigational Site

City

Chieti Scalo

Country

Italy

Facility Name

205.452.39001 Boehringer Ingelheim Investigational Site

City

Firenze

Country

Italy

Facility Name

205.452.39021 Boehringer Ingelheim Investigational Site

City

Monza

Country

Italy

Facility Name

205.452.39014 Boehringer Ingelheim Investigational Site

City

Napoli

Country

Italy

Facility Name

205.452.39012 Boehringer Ingelheim Investigational Site

City

Orbassano (to)

Country

Italy

Facility Name

205.452.39026 Boehringer Ingelheim Investigational Site

City

Orbassano (to)

Country

Italy

Facility Name

205.452.39010 Boehringer Ingelheim Investigational Site

City

Palermo

Country

Italy

Facility Name

205.452.39005 Boehringer Ingelheim Investigational Site

City

Parma

Country

Italy

Facility Name

205.452.39009 Boehringer Ingelheim Investigational Site

City

Perugia

Country

Italy

Facility Name

205.452.39002 Boehringer Ingelheim Investigational Site

City

Prato

Country

Italy

Facility Name

205.452.39030 Boehringer Ingelheim Investigational Site

City

Reggio Emilia

Country

Italy

Facility Name

205.452.39004 Boehringer Ingelheim Investigational Site

City

Roma

Country

Italy

Facility Name

205.452.39017 Boehringer Ingelheim Investigational Site

City

Roma

Country

Italy

Facility Name

205.452.39027 Boehringer Ingelheim Investigational Site

City

Roma

Country

Italy

Facility Name

205.452.39023 Boehringer Ingelheim Investigational Site

City

Treviso

Country

Italy

Facility Name

205.452.82008 Boehringer Ingelheim Investigational Site

City

Bucheon

Country

Korea, Republic of

Facility Name

205.452.82002 Boehringer Ingelheim Investigational Site

City

Busan

Country

Korea, Republic of

Facility Name

205.452.82012 Boehringer Ingelheim Investigational Site

City

Busan

Country

Korea, Republic of

Facility Name

205.452.82010 Boehringer Ingelheim Investigational Site

City

Daegu

Country

Korea, Republic of

Facility Name

205.452.82016 Boehringer Ingelheim Investigational Site

City

Daejoen

Country

Korea, Republic of

Facility Name

205.452.82009 Boehringer Ingelheim Investigational Site

City

Gangwon-Do

Country

Korea, Republic of

Facility Name

205.452.82017 Boehringer Ingelheim Investigational Site

City

Goyang

Country

Korea, Republic of

Facility Name

205.452.82004 Boehringer Ingelheim Investigational Site

City

Gwangju

Country

Korea, Republic of

Facility Name

205.452.82005 Boehringer Ingelheim Investigational Site

City

Incheon

Country

Korea, Republic of

Facility Name

205.452.82020 Boehringer Ingelheim Investigational Site

City

Jeonju

Country

Korea, Republic of

Facility Name

205.452.82001 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82003 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82006 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82007 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82011 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82013 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82014 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82015 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82018 Boehringer Ingelheim Investigational Site

City

Seoul

Country

Korea, Republic of

Facility Name

205.452.82019 Boehringer Ingelheim Investigational Site

City

Uijeongbu

Country

Korea, Republic of

Facility Name

205.452.37106 Boehringer Ingelheim Investigational Site

City

Daugavpils

Country

Latvia

Facility Name

205.452.37107 Boehringer Ingelheim Investigational Site

City

Daugavpils

Country

Latvia

Facility Name

205.452.37108 Boehringer Ingelheim Investigational Site

City

Daugavpils

Country

Latvia

Facility Name

205.452.37102 Boehringer Ingelheim Investigational Site

City

Kraslava

Country

Latvia

Facility Name

205.452.37104 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.452.37105 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.452.37109 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.452.37110 Boehringer Ingelheim Investigational Site

City

Riga

Country

Latvia

Facility Name

205.452.37101 Boehringer Ingelheim Investigational Site

City

Talsi

Country

Latvia

Facility Name

205.452.37103 Boehringer Ingelheim Investigational Site

City

Valmiera

Country

Latvia

Facility Name

205.452.37003 Boehringer Ingelheim Investigational Site

City

Alytus

Country

Lithuania

Facility Name

205.452.37001 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.452.37002 Boehringer Ingelheim Investigational Site

City

Kaunas

Country

Lithuania

Facility Name

205.452.37005 Boehringer Ingelheim Investigational Site

City

Klaipeda

Country

Lithuania

Facility Name

205.452.37007 Boehringer Ingelheim Investigational Site

City

Siauliai

Country

Lithuania

Facility Name

205.452.37011 Boehringer Ingelheim Investigational Site

City

Utena

Country

Lithuania

Facility Name

205.452.37004 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.452.37008 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.452.37010 Boehringer Ingelheim Investigational Site

City

Vilnius

Country

Lithuania

Facility Name

205.452.60006 Boehringer Ingelheim Investigational Site

City

Johor Bahru

Country

Malaysia

Facility Name

205.452.60001 Boehringer Ingelheim Investigational Site

City

Kuala Lumpur

Country

Malaysia

Facility Name

205.452.60002 Boehringer Ingelheim Investigational Site

City

Kuala Lumpur

Country

Malaysia

Facility Name

205.452.60004 Boehringer Ingelheim Investigational Site

City

Kuala Lumpur

Country

Malaysia

Facility Name

205.452.60008 Boehringer Ingelheim Investigational Site

City

Pahang

Country

Malaysia

Facility Name

205.452.60005 Boehringer Ingelheim Investigational Site

City

Sarawak

Country

Malaysia

Facility Name

205.452.60009 Boehringer Ingelheim Investigational Site

City

Selangor

Country

Malaysia

Facility Name

205.452.60007 Boehringer Ingelheim Investigational Site

City

Terengganu

Country

Malaysia

Facility Name

205.452.52004 Boehringer Ingelheim Investigational Site

City

Aguascalientes

Country

Mexico

Facility Name

205.452.52007 Boehringer Ingelheim Investigational Site

City

Distrito Federal

Country

Mexico

Facility Name

205.452.52005 Boehringer Ingelheim Investigational Site

City

Guadalajara

Country

Mexico

Facility Name

205.452.52002 Boehringer Ingelheim Investigational Site

City

Monte Rey

Country

Mexico

Facility Name

205.452.52001 Boehringer Ingelheim Investigational Site

City

México

Country

Mexico

Facility Name

205.452.52003 Boehringer Ingelheim Investigational Site

City

Zona Río

Country

Mexico

Facility Name

205.452.31001 Boehringer Ingelheim Investigational Site

City

Almere

Country

Netherlands

Facility Name

205.452.31008 Boehringer Ingelheim Investigational Site

City

Andijk

Country

Netherlands

Facility Name

205.452.31012 Boehringer Ingelheim Investigational Site

City

Beek En Donk

Country

Netherlands

Facility Name

205.452.31002 Boehringer Ingelheim Investigational Site

City

Beek

Country

Netherlands

Facility Name

205.452.31003 Boehringer Ingelheim Investigational Site

City

Ermelo

Country

Netherlands

Facility Name

205.452.31010 Boehringer Ingelheim Investigational Site

City

Hoogwoud

Country

Netherlands

Facility Name

205.452.31011 Boehringer Ingelheim Investigational Site

City

Nijverdal

Country

Netherlands

Facility Name

205.452.31007 Boehringer Ingelheim Investigational Site

City

Oude Pekela

Country

Netherlands

Facility Name

205.452.31005 Boehringer Ingelheim Investigational Site

City

Roelofarendsveen

Country

Netherlands

Facility Name

205.452.64004 Boehringer Ingelheim Investigational Site

City

Christchurch

Country

New Zealand

Facility Name

205.452.64003 Boehringer Ingelheim Investigational Site

City

Dunedin

Country

New Zealand

Facility Name

205.452.64002 Boehringer Ingelheim Investigational Site

City

Newtown Wellington NZ

Country

New Zealand

Facility Name

205.452.64001 Boehringer Ingelheim Investigational Site

City

Tauranga

Country

New Zealand

Facility Name

205.452.47008 Boehringer Ingelheim Investigational Site

City

Drammen

Country

Norway

Facility Name

205.452.47009 Boehringer Ingelheim Investigational Site

City

Fredrikstad

Country

Norway

Facility Name

205.452.47001 Boehringer Ingelheim Investigational Site

City

Hønefoss

Country

Norway

Facility Name

205.452.47010 Boehringer Ingelheim Investigational Site

City

Kløfta

Country

Norway

Facility Name

205.452.47007 Boehringer Ingelheim Investigational Site

City

Kolbjørnsvik

Country

Norway

Facility Name

205.452.47005 Boehringer Ingelheim Investigational Site

City

Løvenstad

Country

Norway

Facility Name

205.452.47002 Boehringer Ingelheim Investigational Site

City

Oslo

Country

Norway

Facility Name

205.452.47003 Boehringer Ingelheim Investigational Site

City

Oslo

Country

Norway

Facility Name

205.452.47011 Boehringer Ingelheim Investigational Site

City

Oslo

Country

Norway

Facility Name

205.452.47012 Boehringer Ingelheim Investigational Site

City

Sandvika

Country

Norway

Facility Name

205.452.47004 Boehringer Ingelheim Investigational Site

City

Svelvik

Country

Norway

Facility Name

205.452.47006 Boehringer Ingelheim Investigational Site

City

Trollåsen

Country

Norway

Facility Name

205.452.50703 Boehringer Ingelheim Investigational Site

City

Carrasquilla

Country

Panama

Facility Name

205.452.50701 Boehringer Ingelheim Investigational Site

City

Marbella

Country

Panama

Facility Name

205.452.50702 Boehringer Ingelheim Investigational Site

City

Marbella

Country

Panama

Facility Name

205.452.51002 Boehringer Ingelheim Investigational Site

City

Bellavista

Country

Peru

Facility Name

205.452.51003 Boehringer Ingelheim Investigational Site

City

Cusco

Country

Peru

Facility Name

205.452.51004 Boehringer Ingelheim Investigational Site

City

Jesús Maria

Country

Peru

Facility Name

205.452.51007 Boehringer Ingelheim Investigational Site

City

Jesús María

Country

Peru

Facility Name

205.452.51005 Boehringer Ingelheim Investigational Site

City

Lima

Country

Peru

Facility Name

205.452.51001 Boehringer Ingelheim Investigational Site

City

San Isidro

Country

Peru

Facility Name

205.452.51006 Boehringer Ingelheim Investigational Site

City

San Martin de Porres

Country

Peru

Facility Name

205.452.63004 Boehringer Ingelheim Investigational Site

City

Cavite City

Country

Philippines

Facility Name

205.452.63002 Boehringer Ingelheim Investigational Site

City

Davao City

Country

Philippines

Facility Name

205.452.63003 Boehringer Ingelheim Investigational Site

City

Iloilo City

Country

Philippines

Facility Name

205.452.63006 Boehringer Ingelheim Investigational Site

City

Iloilo City

Country

Philippines

Facility Name

205.452.63001 Boehringer Ingelheim Investigational Site

City

Manila

Country

Philippines

Facility Name

205.452.63008 Boehringer Ingelheim Investigational Site

City

Manila

Country

Philippines

Facility Name

205.452.63005 Boehringer Ingelheim Investigational Site

City

Quezon City

Country

Philippines

Facility Name

205.452.63007 Boehringer Ingelheim Investigational Site

City

Quezon City

Country

Philippines

Facility Name

205.452.48031 Boehringer Ingelheim Investigational Site

City

Babice

Country

Poland

Facility Name

205.452.48003 Boehringer Ingelheim Investigational Site

City

Bialystok

Country

Poland

Facility Name

205.452.48011 Boehringer Ingelheim Investigational Site

City

Bialystok

Country

Poland

Facility Name

205.452.48014 Boehringer Ingelheim Investigational Site

City

Bydgoszcz

Country

Poland

Facility Name

205.452.48008 Boehringer Ingelheim Investigational Site

City

Checiny

Country

Poland

Facility Name

205.452.48016 Boehringer Ingelheim Investigational Site

City

Gdansk

Country

Poland

Facility Name

205.452.48019 Boehringer Ingelheim Investigational Site

City

Gdynia

Country

Poland

Facility Name

205.452.48037 Boehringer Ingelheim Investigational Site

City

Gorzow Wlkp

Country

Poland

Facility Name

205.452.48015 Boehringer Ingelheim Investigational Site

City

Ilawa

Country

Poland

Facility Name

205.452.48033 Boehringer Ingelheim Investigational Site

City

Katowice

Country

Poland

Facility Name

205.452.48039 Boehringer Ingelheim Investigational Site

City

Katowice

Country

Poland

Facility Name

205.452.48044 Boehringer Ingelheim Investigational Site

City

Katowice

Country

Poland

Facility Name

205.452.48009 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.452.48021 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.452.48029 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.452.48030 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.452.48048 Boehringer Ingelheim Investigational Site

City

Krakow

Country

Poland

Facility Name

205.452.48043 Boehringer Ingelheim Investigational Site

City

Libiaz

Country

Poland

Facility Name

205.452.48002 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.452.48051 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.452.48056 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.452.48059 Boehringer Ingelheim Investigational Site

City

Lodz

Country

Poland

Facility Name

205.452.48018 Boehringer Ingelheim Investigational Site

City

Olsztyn

Country

Poland

Facility Name

205.452.48025 Boehringer Ingelheim Investigational Site

City

Ostrow Wielkopolska

Country

Poland

Facility Name

205.452.48012 Boehringer Ingelheim Investigational Site

City

Piaseczno

Country

Poland

Facility Name

205.452.48040 Boehringer Ingelheim Investigational Site

City

Piaseczno

Country

Poland

Facility Name

205.452.48026 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.452.48027 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.452.48058 Boehringer Ingelheim Investigational Site

City

Poznan

Country

Poland

Facility Name

205.452.48060 Boehringer Ingelheim Investigational Site

City

Rokietnica

Country

Poland

Facility Name

205.452.48001 Boehringer Ingelheim Investigational Site

City

Skierniewice

Country

Poland

Facility Name

205.452.48032 Boehringer Ingelheim Investigational Site

City

Slawkow

Country

Poland

Facility Name

205.452.48036 Boehringer Ingelheim Investigational Site

City

Szczecin

Country

Poland

Facility Name

205.452.48045 Boehringer Ingelheim Investigational Site

City

Tarnow

Country

Poland

Facility Name

205.452.48057 Boehringer Ingelheim Investigational Site

City

Tczew

Country

Poland

Facility Name

205.452.48004 Boehringer Ingelheim Investigational Site

City

Torun

Country

Poland

Facility Name

205.452.48007 Boehringer Ingelheim Investigational Site

City

Tranow

Country

Poland

Facility Name

205.452.48053 Boehringer Ingelheim Investigational Site

City

Turek

Country

Poland

Facility Name

205.452.48034 Boehringer Ingelheim Investigational Site

City

Warsaw

Country

Poland

Facility Name

205.452.48042 Boehringer Ingelheim Investigational Site

City

Warszawa

Country

Poland

Facility Name

205.452.48049 Boehringer Ingelheim Investigational Site

City

Warszawa

Country

Poland

Facility Name

205.452.48017 Boehringer Ingelheim Investigational Site

City

Wolomin

Country

Poland

Facility Name

205.452.48006 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.452.48028 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.452.48035 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.452.48038 Boehringer Ingelheim Investigational Site

City

Wroclaw

Country

Poland

Facility Name

205.452.48022 Boehringer Ingelheim Investigational Site

City

Zakopane

Country

Poland

Facility Name

205.452.35103 Boehringer Ingelheim Investigational Site

City

Amadora

Country

Portugal

Facility Name

205.452.35102 Boehringer Ingelheim Investigational Site

City

Coimbra

Country

Portugal

Facility Name

205.452.35107 Boehringer Ingelheim Investigational Site

City

Lisboa

Country

Portugal

Facility Name

205.452.35108 Boehringer Ingelheim Investigational Site

City

Lisboa

Country

Portugal

Facility Name

205.452.35101 Boehringer Ingelheim Investigational Site

City

Matosinhos

Country

Portugal

Facility Name

205.452.35105 Boehringer Ingelheim Investigational Site

City

Penafiel

Country

Portugal

Facility Name

205.452.35106 Boehringer Ingelheim Investigational Site

City

Vila Nova de Gaia

Country

Portugal

Facility Name

205.452.35104 Boehringer Ingelheim Investigational Site

City

Viseu

Country

Portugal

Facility Name

205.452.01177 Boehringer Ingelheim Investigational Site

City

Ponce

Country

Puerto Rico

Facility Name

205.452.01162 Boehringer Ingelheim Investigational Site

City

San Juan

Country

Puerto Rico

Facility Name

205.452.40008 Boehringer Ingelheim Investigational Site

City

Brasov

Country

Romania

Facility Name

205.452.40012 Boehringer Ingelheim Investigational Site

City

Brasov

Country

Romania

Facility Name

205.452.40001 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.452.40003 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.452.40004 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.452.40007 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.452.40009 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.452.40013 Boehringer Ingelheim Investigational Site

City

Bucharest

Country

Romania

Facility Name

205.452.40002 Boehringer Ingelheim Investigational Site

City

Bucuresti

Country

Romania

Facility Name

205.452.40011 Boehringer Ingelheim Investigational Site

City

Constanta

Country

Romania

Facility Name

205.452.40006 Boehringer Ingelheim Investigational Site

City

Craiova

Country

Romania

Facility Name

205.452.07030 Boehringer Ingelheim Investigational Site

City

Arkhangelsk

Country

Russian Federation

Facility Name

205.452.07049 Boehringer Ingelheim Investigational Site

City

Barnaul

Country

Russian Federation

Facility Name

205.452.07054 Boehringer Ingelheim Investigational Site

City

Barnaul

Country

Russian Federation

Facility Name

205.452.07053 Boehringer Ingelheim Investigational Site

City

Chelyabinsk

Country

Russian Federation

Facility Name

205.452.07031 Boehringer Ingelheim Investigational Site

City

Ekaterinburg

Country

Russian Federation

Facility Name

205.452.07038 Boehringer Ingelheim Investigational Site

City

Gatchina (Leningradskaya oblast)

Country

Russian Federation

Facility Name

205.452.07036 Boehringer Ingelheim Investigational Site

City

Irkutsk

Country

Russian Federation

Facility Name

205.452.07001 Boehringer Ingelheim Investigational Site

City

Ivanovo

Country

Russian Federation

Facility Name

205.452.07023 Boehringer Ingelheim Investigational Site

City

Kaliningrad

Country

Russian Federation

Facility Name

205.452.07003 Boehringer Ingelheim Investigational Site

City

Kazan

Country

Russian Federation

Facility Name

205.452.07005 Boehringer Ingelheim Investigational Site

City

Kazan

Country

Russian Federation

Facility Name

205.452.07007 Boehringer Ingelheim Investigational Site

City

Kazan

Country

Russian Federation

Facility Name

205.452.07048 Boehringer Ingelheim Investigational Site

City

Kemerovo

Country

Russian Federation

Facility Name

205.452.07060 Boehringer Ingelheim Investigational Site

City

Kemerovo

Country

Russian Federation

Facility Name

205.452.07059 Boehringer Ingelheim Investigational Site

City

Kirov

Country

Russian Federation

Facility Name

205.452.07009 Boehringer Ingelheim Investigational Site

City

Krasnodar

Country

Russian Federation

Facility Name

205.452.07010 Boehringer Ingelheim Investigational Site

City

Krasnodar

Country

Russian Federation

Facility Name

205.452.07013 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07020 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07021 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07026 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07027 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07028 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07029 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07043 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07045 Boehringer Ingelheim Investigational Site

City

Moscow

Country

Russian Federation

Facility Name

205.452.07004 Boehringer Ingelheim Investigational Site

City

Murmansk

Country

Russian Federation

Facility Name

205.452.07055 Boehringer Ingelheim Investigational Site

City

Nizhniy Novgorod

Country

Russian Federation

Facility Name

205.452.07051 Boehringer Ingelheim Investigational Site

City

Nizhny Novgorod

Country

Russian Federation

Facility Name

205.452.07037 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.452.07040 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.452.07042 Boehringer Ingelheim Investigational Site

City

Novosibirsk

Country

Russian Federation

Facility Name

205.452.07041 Boehringer Ingelheim Investigational Site

City

Penza

Country

Russian Federation

Facility Name

205.452.07050 Boehringer Ingelheim Investigational Site

City

Pskov

Country

Russian Federation

Facility Name

205.452.07015 Boehringer Ingelheim Investigational Site

City

Rostov-na-Donu

Country

Russian Federation

Facility Name

205.452.07016 Boehringer Ingelheim Investigational Site

City

Rostov-on-Don

Country

Russian Federation

Facility Name

205.452.07039 Boehringer Ingelheim Investigational Site

City

Ryazan

Country

Russian Federation

Facility Name

205.452.07034 Boehringer Ingelheim Investigational Site

City

Samara

Country

Russian Federation

Facility Name

205.452.07047 Boehringer Ingelheim Investigational Site

City

Saratov

Country

Russian Federation

Facility Name

205.452.07002 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07006 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07011 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07014 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07017 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07018 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07022 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07024 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07025 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07033 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07046 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07052 Boehringer Ingelheim Investigational Site

City

St. Petersburg

Country

Russian Federation

Facility Name

205.452.07032 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.452.07035 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.452.07057 Boehringer Ingelheim Investigational Site

City

Tomsk

Country

Russian Federation

Facility Name

205.452.07019 Boehringer Ingelheim Investigational Site

City

Velikiy Novgorod

Country

Russian Federation

Facility Name

205.452.07044 Boehringer Ingelheim Investigational Site

City

Yaroslavl

Country

Russian Federation

Facility Name

205.452.38103 Boehringer Ingelheim Investigational Site

City

Belgrade

Country

Serbia

Facility Name

205.452.38104 Boehringer Ingelheim Investigational Site

City

Belgrade

Country

Serbia

Facility Name

205.452.38106 Boehringer Ingelheim Investigational Site

City

Belgrade

Country

Serbia

Facility Name

205.452.38107 Boehringer Ingelheim Investigational Site

City

Belgrade

Country

Serbia

Facility Name

205.452.38102 Boehringer Ingelheim Investigational Site

City

Kragujevac

Country

Serbia

Facility Name

205.452.38105 Boehringer Ingelheim Investigational Site

City

Nis

Country

Serbia

Facility Name

205.452.38101 Boehringer Ingelheim Investigational Site

City

Sremska Kamenica

Country

Serbia

Facility Name

205.452.42103 Boehringer Ingelheim Investigational Site

City

Bardejov

Country

Slovakia

Facility Name

205.452.42107 Boehringer Ingelheim Investigational Site

City

Bratislava

Country

Slovakia

Facility Name

205.452.42102 Boehringer Ingelheim Investigational Site

City

Humenne

Country

Slovakia

Facility Name

205.452.42105 Boehringer Ingelheim Investigational Site

City

Kosice

Country

Slovakia

Facility Name

205.452.42111 Boehringer Ingelheim Investigational Site

City

Kosice

Country

Slovakia

Facility Name

205.452.42113 Boehringer Ingelheim Investigational Site

City

Kosice

Country

Slovakia

Facility Name

205.452.42108 Boehringer Ingelheim Investigational Site

City

Levice

Country

Slovakia

Facility Name

205.452.42109 Boehringer Ingelheim Investigational Site

City

Martin

Country

Slovakia

Facility Name

205.452.42112 Boehringer Ingelheim Investigational Site

City

Poprad

Country

Slovakia

Facility Name

205.452.42101 Boehringer Ingelheim Investigational Site

City

Presov

Country

Slovakia

Facility Name

205.452.42104 Boehringer Ingelheim Investigational Site

City

Rimavska Sobota

Country

Slovakia

Facility Name

205.452.42106 Boehringer Ingelheim Investigational Site

City

Spisska Nova Ves

Country

Slovakia

Facility Name

205.452.42110 Boehringer Ingelheim Investigational Site

City

Sturovo

Country

Slovakia

Facility Name

205.452.27013 Boehringer Ingelheim Investigational Site

City

Amanzimtoti

Country

South Africa

Facility Name

205.452.27002 Boehringer Ingelheim Investigational Site

City

Bellville

Country

South Africa

Facility Name

205.452.27010 Boehringer Ingelheim Investigational Site

City

Bloemfontein

Country

South Africa

Facility Name

205.452.27001 Boehringer Ingelheim Investigational Site

City

Cape Town

Country

South Africa

Facility Name

205.452.27004 Boehringer Ingelheim Investigational Site

City

Cape Town

Country

South Africa

Facility Name

205.452.27008 Boehringer Ingelheim Investigational Site

City

Cape Town

Country

South Africa

Facility Name

205.452.27011 Boehringer Ingelheim Investigational Site

City

Cape Town

Country

South Africa

Facility Name

205.452.27012 Boehringer Ingelheim Investigational Site

City

Cape Town

Country

South Africa

Facility Name

205.452.27006 Boehringer Ingelheim Investigational Site

City

Centurion

Country

South Africa

Facility Name

205.452.27003 Boehringer Ingelheim Investigational Site

City

Durban

Country

South Africa

Facility Name

205.452.27014 Boehringer Ingelheim Investigational Site

City

Johannesburg

Country

South Africa

Facility Name

205.452.27005 Boehringer Ingelheim Investigational Site

City

Pretoria

Country

South Africa

Facility Name

205.452.27009 Boehringer Ingelheim Investigational Site

City

Pretoria

Country

South Africa

Facility Name

205.452.27007 Boehringer Ingelheim Investigational Site

City

Somerset West

Country

South Africa

Facility Name

205.452.34018 Boehringer Ingelheim Investigational Site

City

Badajoz

Country

Spain

Facility Name

205.452.34021 Boehringer Ingelheim Investigational Site

City

Badalona (Barcelona)

Country

Spain

Facility Name

205.452.34010 Boehringer Ingelheim Investigational Site

City

Barcelona

Country

Spain

Facility Name

205.452.34025 Boehringer Ingelheim Investigational Site

City

Barcelona

Country

Spain

Facility Name

205.452.34027 Boehringer Ingelheim Investigational Site

City

Centelles

Country

Spain

Facility Name

205.452.34015 Boehringer Ingelheim Investigational Site

City

Cáceres

Country

Spain

Facility Name

205.452.34016 Boehringer Ingelheim Investigational Site

City

Elda

Country

Spain

Facility Name

205.452.34008 Boehringer Ingelheim Investigational Site

City

Hospitalet de Llobregat

Country

Spain

Facility Name

205.452.34026 Boehringer Ingelheim Investigational Site

City

Lugo

Country

Spain

Facility Name

205.452.34011 Boehringer Ingelheim Investigational Site

City

Madrid

Country

Spain

Facility Name

205.452.34019 Boehringer Ingelheim Investigational Site

City

Madrid

Country

Spain

Facility Name

205.452.34020 Boehringer Ingelheim Investigational Site

City

Málaga

Country

Spain

Facility Name

205.452.34002 Boehringer Ingelheim Investigational Site

City

Mérida

Country

Spain

Facility Name

205.452.34017 Boehringer Ingelheim Investigational Site

City

Plasencia

Country

Spain

Facility Name

205.452.34001 Boehringer Ingelheim Investigational Site

City

Pozuelo de Alarcón

Country

Spain

Facility Name

205.452.34024 Boehringer Ingelheim Investigational Site

City

San Juan de Alicante

Country

Spain

Facility Name

205.452.34003 Boehringer Ingelheim Investigational Site

City

Santander

Country

Spain

Facility Name

205.452.34005 Boehringer Ingelheim Investigational Site

City

Terrassa (Barcelona)

Country

Spain

Facility Name

205.452.34007 Boehringer Ingelheim Investigational Site

City

Torrevieja

Country

Spain

Facility Name

205.452.34012 Boehringer Ingelheim Investigational Site

City

Valencia

Country

Spain

Facility Name

205.452.34013 Boehringer Ingelheim Investigational Site

City

Valladolid

Country

Spain

Facility Name

205.452.34009 Boehringer Ingelheim Investigational Site

City

Vic (Barcelona)

Country

Spain

Facility Name

205.452.34023 Boehringer Ingelheim Investigational Site

City

Vilanova i la Geltrú

Country

Spain

Facility Name

205.452.34004 Boehringer Ingelheim Investigational Site

City

Zaragoza

Country

Spain

Facility Name

205.452.46005 Boehringer Ingelheim Investigational Site

City

Brämhult

Country

Sweden

Facility Name

205.452.46014 Boehringer Ingelheim Investigational Site

City

Eksjö

Country

Sweden

Facility Name

205.452.46012 Boehringer Ingelheim Investigational Site

City

Gullspång

Country

Sweden

Facility Name

205.452.46013 Boehringer Ingelheim Investigational Site

City

Göteborg

Country

Sweden

Facility Name

205.452.46001 Boehringer Ingelheim Investigational Site

City

Höllviken

Country

Sweden

Facility Name

205.452.46008 Boehringer Ingelheim Investigational Site

City

Järfälla

Country

Sweden

Facility Name

205.452.46009 Boehringer Ingelheim Investigational Site

City

Kil

Country

Sweden

Facility Name

205.452.46007 Boehringer Ingelheim Investigational Site

City

Lidingö

Country

Sweden

Facility Name

205.452.46003 Boehringer Ingelheim Investigational Site

City

Luleå

Country

Sweden

Facility Name

205.452.46010 Boehringer Ingelheim Investigational Site

City

Sigtuna

Country

Sweden

Facility Name

205.452.46002 Boehringer Ingelheim Investigational Site

City

Solna

Country

Sweden

Facility Name

205.452.46011 Boehringer Ingelheim Investigational Site

City

Uddevalla

Country

Sweden

Facility Name

205.452.46006 Boehringer Ingelheim Investigational Site

City

Örebro

Country

Sweden

Facility Name

205.452.41003 Boehringer Ingelheim Investigational Site

City

Ascona

Country

Switzerland

Facility Name

205.452.41004 Boehringer Ingelheim Investigational Site

City

Basel

Country

Switzerland

Facility Name

205.452.41016 Boehringer Ingelheim Investigational Site

City

Bern

Country

Switzerland

Facility Name

205.452.41012 Boehringer Ingelheim Investigational Site

City

Glarus

Country

Switzerland

Facility Name

205.452.41001 Boehringer Ingelheim Investigational Site

City

Gossau

Country

Switzerland

Facility Name

205.452.41015 Boehringer Ingelheim Investigational Site

City

Liestal

Country

Switzerland

Facility Name

205.452.41010 Boehringer Ingelheim Investigational Site

City

Locarno

Country

Switzerland

Facility Name

205.452.41011 Boehringer Ingelheim Investigational Site

City

Lugano

Country

Switzerland

Facility Name

205.452.41007 Boehringer Ingelheim Investigational Site

City

Spiez

Country

Switzerland

Facility Name

205.452.41002 Boehringer Ingelheim Investigational Site

City

St. Gallen

Country

Switzerland

Facility Name

205.452.41009 Boehringer Ingelheim Investigational Site

City

St. Gallen

Country

Switzerland

Facility Name

205.452.41013 Boehringer Ingelheim Investigational Site

City

Zürich

Country

Switzerland

Facility Name

205.452.41014 Boehringer Ingelheim Investigational Site

City

Zürich

Country

Switzerland

Facility Name

205.452.88607 Boehringer Ingelheim Investigational Site

City

Changhua

Country

Taiwan

Facility Name

205.452.88614 Boehringer Ingelheim Investigational Site

City

Chia-Yi

Country

Taiwan

Facility Name

205.452.88608 Boehringer Ingelheim Investigational Site

City

Kaohsiung City

Country

Taiwan

Facility Name

205.452.88609 Boehringer Ingelheim Investigational Site

City

Kaohsiung City

Country

Taiwan

Facility Name

205.452.88611 Boehringer Ingelheim Investigational Site

City

Kaohsiung

Country

Taiwan

Facility Name

205.452.88604 Boehringer Ingelheim Investigational Site

City

New Taipei

Country

Taiwan

Facility Name

205.452.88605 Boehringer Ingelheim Investigational Site

City

Taichung

Country

Taiwan

Facility Name

205.452.88606 Boehringer Ingelheim Investigational Site

City

Taichung

Country

Taiwan

Facility Name

205.452.88612 Boehringer Ingelheim Investigational Site

City

Taichung

Country

Taiwan

Facility Name

205.452.88610 Boehringer Ingelheim Investigational Site

City

Tainan

Country

Taiwan

Facility Name

205.452.88602 Boehringer Ingelheim Investigational Site

City

Taipei

Country

Taiwan

Facility Name

205.452.88603 Boehringer Ingelheim Investigational Site

City

Taipei

Country

Taiwan

Facility Name

205.452.88613 Boehringer Ingelheim Investigational Site

City

Taipei

Country

Taiwan

Facility Name

205.452.88601 Boehringer Ingelheim Investigational Site

City

Taoyuan County

Country

Taiwan

Facility Name

205.452.66004 Boehringer Ingelheim Investigational Site

City

Chiang Mai

Country

Thailand

Facility Name

205.452.66003 Boehringer Ingelheim Investigational Site

City

Hatyai, Songkhla

Country

Thailand

Facility Name

205.452.66002 Boehringer Ingelheim Investigational Site

City

Khon Kaen

Country

Thailand

Facility Name

205.452.66005 Boehringer Ingelheim Investigational Site

City

Muang, Phitsanulok

Country

Thailand

Facility Name

205.452.66001 Boehringer Ingelheim Investigational Site

City

Nonthaburi

Country

Thailand

Facility Name

205.452.21603 Boehringer Ingelheim Investigational Site

City

Ariana

Country

Tunisia

Facility Name

205.452.21605 Boehringer Ingelheim Investigational Site

City

Ariana

Country

Tunisia

Facility Name

205.452.21606 Boehringer Ingelheim Investigational Site

City

Ariana

Country

Tunisia

Facility Name

205.452.21607 Boehringer Ingelheim Investigational Site

City

Ariana

Country

Tunisia

Facility Name

205.452.21610 Boehringer Ingelheim Investigational Site

City

Mahdia

Country

Tunisia

Facility Name

205.452.21609 Boehringer Ingelheim Investigational Site

City

Monastir

Country

Tunisia

Facility Name

205.452.21608 Boehringer Ingelheim Investigational Site

City

Nabeul

Country

Tunisia

Facility Name

205.452.21601 Boehringer Ingelheim Investigational Site

City

Tunis

Country

Tunisia

Facility Name

205.452.21602 Boehringer Ingelheim Investigational Site

City

Tunis

Country

Tunisia

Facility Name

205.452.21604 Boehringer Ingelheim Investigational Site

City

Tunis

Country

Tunisia

Facility Name

205.452.90001 Boehringer Ingelheim Investigational Site

City

Adana

Country

Turkey

Facility Name

205.452.90008 Boehringer Ingelheim Investigational Site

City

Ankara

Country

Turkey

Facility Name

205.452.90013 Boehringer Ingelheim Investigational Site

City

Ankara

Country

Turkey

Facility Name

205.452.90005 Boehringer Ingelheim Investigational Site

City

Antalya

Country

Turkey

Facility Name

205.452.90018 Boehringer Ingelheim Investigational Site

City

Aydin

Country

Turkey

Facility Name

205.452.90003 Boehringer Ingelheim Investigational Site

City

Bolu

Country

Turkey

Facility Name

205.452.90006 Boehringer Ingelheim Investigational Site

City

Edirne

Country

Turkey

Facility Name

205.452.90010 Boehringer Ingelheim Investigational Site

City

Erzurum

Country

Turkey

Facility Name

205.452.90019 Boehringer Ingelheim Investigational Site

City

Hatay

Country

Turkey

Facility Name

205.452.90017 Boehringer Ingelheim Investigational Site

City

Istanbul

Country

Turkey

Facility Name

205.452.90020 Boehringer Ingelheim Investigational Site

City

Istanbul

Country

Turkey

Facility Name

205.452.90021 Boehringer Ingelheim Investigational Site

City

Istanbul

Country

Turkey

Facility Name

205.452.90015 Boehringer Ingelheim Investigational Site

City

Izmir

Country

Turkey

Facility Name

205.452.90016 Boehringer Ingelheim Investigational Site

City

Izmir

Country

Turkey

Facility Name

205.452.90022 Boehringer Ingelheim Investigational Site

City

Izmir

Country

Turkey

Facility Name

205.452.90007 Boehringer Ingelheim Investigational Site

City

Malatya

Country

Turkey

Facility Name

205.452.38028 Boehringer Ingelheim Investigational Site

City

Crimea

Country

Ukraine

Facility Name

205.452.38024 Boehringer Ingelheim Investigational Site

City

Dnipropetrovks

Country

Ukraine

Facility Name

205.452.38022 Boehringer Ingelheim Investigational Site

City

Dnipropetrovsk

Country

Ukraine

Facility Name

205.452.38034 Boehringer Ingelheim Investigational Site

City

Dnyepropyetrovsk

Country

Ukraine

Facility Name

205.452.38002 Boehringer Ingelheim Investigational Site

City

Donetsk

Country

Ukraine

Facility Name

205.452.38020 Boehringer Ingelheim Investigational Site

City

Donetsk

Country

Ukraine

Facility Name

205.452.38011 Boehringer Ingelheim Investigational Site

City

Ivano-Frankivsk

Country

Ukraine

Facility Name

205.452.38005 Boehringer Ingelheim Investigational Site

City

Kharkiv

Country

Ukraine

Facility Name

205.452.38001 Boehringer Ingelheim Investigational Site

City

Kharkov

Country

Ukraine

Facility Name

205.452.38004 Boehringer Ingelheim Investigational Site

City

Kharkov

Country

Ukraine

Facility Name

205.452.38006 Boehringer Ingelheim Investigational Site

City

Kharkov

Country

Ukraine

Facility Name

205.452.38008 Boehringer Ingelheim Investigational Site

City

Kharkov

Country

Ukraine

Facility Name

205.452.38018 Boehringer Ingelheim Investigational Site

City

Kharkov

Country

Ukraine

Facility Name

205.452.38003 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.452.38010 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.452.38012 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.452.38013 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.452.38015 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.452.38032 Boehringer Ingelheim Investigational Site

City

Kiev

Country

Ukraine

Facility Name

205.452.38026 Boehringer Ingelheim Investigational Site

City

Nikolayev

Country

Ukraine

Facility Name

205.452.38023 Boehringer Ingelheim Investigational Site

City

Odesa

Country

Ukraine

Facility Name

205.452.38027 Boehringer Ingelheim Investigational Site

City

Odessa

Country

Ukraine

Facility Name

205.452.38031 Boehringer Ingelheim Investigational Site

City

Odessa

Country

Ukraine

Facility Name

205.452.38017 Boehringer Ingelheim Investigational Site

City

Simferopol

Country

Ukraine

Facility Name

205.452.38019 Boehringer Ingelheim Investigational Site

City

Vinnytsya

Country

Ukraine

Facility Name

205.452.38030 Boehringer Ingelheim Investigational Site

City

Zaporizhzhya

Country

Ukraine

Facility Name

205.452.44010 Boehringer Ingelheim Investigational Site

City

Atherstone

Country

United Kingdom

Facility Name

205.452.44008 Boehringer Ingelheim Investigational Site

City

Burbage

Country

United Kingdom

Facility Name

205.452.44004 Boehringer Ingelheim Investigational Site

City

Chertsey

Country

United Kingdom

Facility Name

205.452.44002 Boehringer Ingelheim Investigational Site

City

Chesterfield

Country

United Kingdom

Facility Name

205.452.44003 Boehringer Ingelheim Investigational Site

City

Coventry

Country

United Kingdom

Facility Name

205.452.44001 Boehringer Ingelheim Investigational Site

City

Exeter

Country

United Kingdom

Facility Name

205.452.44007 Boehringer Ingelheim Investigational Site

City

Fowey

Country

United Kingdom

Facility Name

205.452.44005 Boehringer Ingelheim Investigational Site

City

Frome

Country

United Kingdom

Facility Name

205.452.44011 Boehringer Ingelheim Investigational Site

City

Leamington Spa

Country

United Kingdom

Facility Name

205.452.44006 Boehringer Ingelheim Investigational Site

City

St Just, Penzance

Country

United Kingdom

12. IPD Sharing Statement

Citations:

PubMed Identifier

29497289

Citation

Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(R) trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. doi: 10.2147/COPD.S148393. eCollection 2018.

Results Reference

derived

PubMed Identifier

28957643

Citation

Calverley PMA, Mueller A, Fowler A, Metzdorf N, Wise RA. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants. Ann Am Thorac Soc. 2018 Feb;15(2):200-208. doi: 10.1513/AnnalsATS.201703-194OC.

Results Reference

derived

PubMed Identifier

26715479

Citation

Dahl R, Calverley PM, Anzueto A, Metzdorf N, Fowler A, Mueller A, Wise R, Dusser D. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open. 2015 Dec 29;5(12):e009015. doi: 10.1136/bmjopen-2015-009015.

Results Reference

derived

PubMed Identifier

26369563

Citation

Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R. The Tiotropium Safety and Performance in Respimat(R) (TIOSPIR(R)) Trial: Spirometry Outcomes. Respir Res. 2015 Sep 15;16(1):107. doi: 10.1186/s12931-015-0269-4.

Results Reference

derived

PubMed Identifier

23992515

Citation

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

Results Reference

derived

Links:

URL

http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.452_U13-3560-01.pdf

Description

Related Info

URL

http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.452_Literature.pdf

Description

Related Info

Learn more about this trial

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

We'll reach out to this number within 24 hrs

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial